

UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL
FACULDADE DE MEDICINA
PROGRAMA DE PÓS-GRADUAÇÃO EM ALIMENTAÇÃO, NUTRIÇÃO E SAÚDE

AVALIAÇÃO NUTRICIONAL EM PACIENTES IDOSOS COM TUMORES

SÓLIDOS:

**COMPLEMENTARIEDADE DE INSTRUMENTOS PARA PREDIZER TEMPO DE
INTERNAÇÃO PROLONGADA E READMISSÃO HOSPITALAR.**

GIOVANNA POTRICK STEFANI

ORIENTADORA: PROF^a. Dr^a. THAIS STEEMBURGO

DISSERTAÇÃO DE MESTRADO

2023

UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL
FACULDADE DE MEDICINA
PROGRAMA DE PÓS-GRADUAÇÃO EM ALIMENTAÇÃO, NUTRIÇÃO E SAÚDE

**AVALIAÇÃO NUTRICIONAL EM PACIENTES IDOSOS COM TUMORES
SÓLIDOS:
COMPLEMENTARIEDADE DE INSTRUMENTOS PARA PREDIZER TEMPO DE
INTERNAÇÃO PROLONGADA E READMISSÃO HOSPITALAR.**

GIOVANNA POTRICK STEFANI

ORIENTADORA: PROF^a. Dr^a. THAIS STEEMBURGO

Dissertação de Mestrado apresentada ao Programa de Pós-Graduação em Nutrição, Alimentação e Saúde da Universidade Federal do Rio Grande do Sul como requisito parcial para obtenção do título de Mestre.

2023

CIP - Catalogação na Publicação

Stefani, Giovanna Potrick

Avaliação nutricional em pacientes idosos com tumores sólidos: Complementariedade de instrumentos para predizer tempo de internação prolongada e readmissão hospitalar. / Giovanna Potrick Stefani. -- 2023.

98 f.

Orientadora: Thais Steemburgo.

Dissertação (Mestrado) -- Universidade Federal do Rio Grande do Sul, Faculdade de Medicina, Programa de Pós-Graduação em Alimentação, Nutrição e Saúde, Porto Alegre, BR-RS, 2023.

1. Câncer. 2. Complementariedade da Desnutrição. 3. Triagem Nutricional. 4. Avaliação Nutricional. 5. Desfechos clínicos. I. Steemburgo, Thais, orient. II. Título.

Agradecimentos

Agradeço inicialmente à minha orientadora, Professora Dr^a Thais Steemburgo, pela paciência e parceria nestes dois anos. Agradeço por ter confiado em mim, sem me conhecer previamente, e aceitado ser minha orientadora nesse processo.

Aos meus pais, por todo apoio e incentivo que nunca faltaram durante a minha caminhada. Ao meu noivo Natan, pelo apoio, amor e paciência em todos os momentos que precisei e, muitas vezes, por ter acreditado mais em mim do que eu mesma. Aos meus amigos, Júlia e Júnior (e Rafinha), por serem abrigo nos momentos mais cansativos.

Agradeço à minha dupla e amiga que o mestrado me proporcionou, nutricionista e mestre Mariana Crestani, pela incansável ajuda e paciência nas inúmeras chamadas de vídeo que fizemos ao longo desses dois anos.

Às alunas Laura Scott e Camilla Horn, pela dedicação e responsabilidade com o projeto e os pacientes.

Aos pacientes que consentiram sua participação colaborando com os principais marcadores avaliados no estudo.

A banca formada pelas Doutoradas Professoras Estela Rabito, Gabriela Correa Souza e Tatiana Pedro de Paula que dispenderam seu tempo para leitura desta dissertação.

À CAPES, pelo auxílio financeiro durante o período do mestrado.

Por fim, agradeço à Universidade Federal do Rio Grande do Sul, ao Programa de Pós-graduação em Alimentação, Nutrição e Saúde e ao Hospital de Clínicas de Porto Alegre.

Formato da dissertação

Essa dissertação segue o formato proposto pelo Programa de Pós-Graduação em Alimentação, Nutrição e Saúde da Universidade Federal do Rio Grande do Sul:

1. Revisão da literatura sobre o tema
2. Artigo Original
3. Anexos

Sumário

Lista de abreviaturas.....	5
Lista de Tabelas e Figuras.....	6
Resumo.....	7
Capítulo I.....	9
Revisão da literatura.....	10
1. Câncer: Conceito e epidemiologia.....	10
2. Desnutrição no paciente idoso e com câncer.....	11
3. Importância da avaliação da nutrição no paciente idoso com câncer	13
4. Instrumentos de avaliação do risco nutricional.....	14
5. Instrumentos de diagnósticos de desnutrição.....	20
6. Complementariedade de instrumentos de avaliação nutricional.....	25
7. Justificativa e objetivos.....	27
8. Referências bibliográficas.....	31
Capítulo II.....	43
Artigo Original.....	44
Abstract.....	46
Introduction.....	47
Materials and Methods.....	48
Results.....	52
Discussion.....	55
Conclusion.....	59
References.....	61
Normas da revista <i>Nutrition</i>	81

Lista de abreviaturas

ASG	Avaliação Subjetiva Global
ASG-PPP	Avaliação Subjetiva Global – Produzida Pelo Paciente
ASG-PPP SF	Avaliação Subjetiva Global – Produzida Pelo Paciente versão reduzida
ASPEN	<i>American Society for Parenteral and Enteral Nutrition</i>
AVC	Acidente Vascular Cerebral
DCNT	Doença Crônica Não Transmissível
ESPEN	<i>European Society for Clinical Nutrition and Metabolism</i>
FELANPE	<i>Federación Latinoamericana de Terapia Nutricional, Nutrición Clínica y Metabolismo</i>
GLIM	<i>Global Leadership Initiative on Malnutrition</i>
IMC	Índice de Massa Corporal
MNA-SF	Mini Avaliação Nutricional versão reduzida
MST	<i>Malnutrition Screening Tool</i>
MUST	<i>Malnutrition Universal Screening Tool</i>
NRS-2002	<i>Nutritional Risk Screening-2002</i>
NUTRIC	Nutrition Risk in Critically Ill
NUTRISCORE	<i>Nutritional screening tool score</i>
PENSA	<i>Parenteral and Enteral Nutrition Society of Asia</i>
SBNO	Sociedade Brasileira de Nutrição Oncológica

Lista de Tabelas e Figuras

Capítulo I

Revisão da literatura

Tabela 1. Instrumentos comuns de triagem nutricional para pacientes hospitalizados

Tabela 2. Instrumentos comuns de diagnóstico de nutrição para pacientes hospitalizados

Capítulo II

Artigo Original

Table 1. *Characteristics of 248 older patients with solid tumors.*

Table 2. *Nutritional characteristics of 248 older patients with solid tumors.*

Table 3. *Accuracy, sensitivity, specificity, predictive positive and negative values of nutritional assessment tools isolated and combined for prediction of hospitalization (≥ 4 days) and readmission (60 days).*

Table 4. *Association of nutritional risk by five screening instruments and malnutrition by three nutritional assessment tools with clinical outcomes.*

Figure 1. *Flowchart of patient selection.*

Figure 2. *Prevalence of nutritional risk according to NRS-2002, MST, MUST, PG-SGA SF and malnutrition by SGA, PG-SGA and GLIM criteria in older patients with solid tumors.*

Figure 3. *Receiver operating characteristic (ROC) curves for prediction of hospitalization ≥ 4 days.*

Resumo

A desnutrição é uma manifestação clínica comum em pacientes hospitalizados e pode levar a desfechos clínicos desfavoráveis como maior tempo de internação, readmissão e mortalidade. Pacientes com câncer tem mais risco de desnutrição que pacientes que não tem câncer. E este cenário é ainda mais preocupante em pacientes idosos com câncer. De fato, o estado nutricional está associado a sobrevida bem como a resposta ao tratamento oncológico. Neste sentido, identificar e diagnosticar precocemente tanto o risco nutricional e a presença da desnutrição beneficiam estes pacientes com uma intervenção nutricional precoce e especializada. Tais diagnósticos são realizados pelos instrumentos de triagem e de avaliação nutricional.

As principais ferramentas de triagem validadas em indivíduos hospitalizados são: [1] *Nutritional Risk Screening-2002* (NRS-2002) – projetada para incluir medidas de desnutrição atual, bem como a gravidade da doença, [2] *Malnutrition Screening Tool* (MST) – uma das ferramentas de triagem amplamente utilizadas e é baseada em apenas duas questões relacionadas à mudança de peso e perda de apetite, [3] *Malnutrition Universal Screening Tool* (MUST) - ferramenta que foi especificamente validada em pacientes com câncer, [4] *Mini Avaliação Nutricional Short Form* (MNA-SF) – desenvolvido para avaliar o risco nutricional particularmente em pacientes idosos, e, [5] *Avaliação Subjetiva Global Produzida pelo Paciente versão reduzida* (ASG-PPP SF) – ferramenta específica para pacientes com câncer. Além disso, para realizar uma avaliação nutricional completa em pacientes com câncer, recomenda-se a utilização da *Avaliação Subjetiva Global* (ASG) – considerada o critério de referência ou ASG-PPP - adaptada da ASG e desenvolvida especificamente para

indivíduos com câncer e, os critérios propostos pelo consenso do *Global Leadership Initiative on Malnutrition* (GLIM) para diagnosticar de desnutrição

Em pacientes adultos com câncer, evidências científicas mostram associação positiva entre alto risco e pior estado nutricional, identificado por diferentes ferramentas, com maior tempo de hospitalização e períodos de reinternação. Em pacientes adultos hospitalizados com câncer instrumentos como NRS-2002, ASG e ASG-PPP foram eficazes para avaliar desfechos clínicos desfavoráveis, no entanto, os dados na população idosa com câncer ainda são escassos. Mais recentemente, estudos vêm demonstrando a importância do uso combinado de instrumentos para obter um prognóstico mais completo e preciso do risco e estado nutricional em pacientes oncológicos. Contudo, até o momento, não há estudo que avaliou a complementariedade dos principais instrumentos de risco nutricional e de diagnóstico nutricional para prever desfechos negativos em indivíduos idosos com câncer.

Considerando que a desnutrição é frequentemente observada em pacientes idosos com câncer e está associada a desfechos clínicos ruins e que estudos sobre a complementariedade neste grupo de indivíduos ainda estão sendo explorados, este estudo teve como objetivo analisar a complementariedade de cinco instrumentos de risco nutricional (NRS-2002, MST, MUST, MNA-SF e ASG-PPP SF) combinados com três ferramentas de diagnóstico de desnutrição (ASG, ASG-PPP e GLIM) e sua capacidade de prever desfechos clínicos desfavoráveis, como tempo de internação e reinternação em 60 dias em pacientes idosos com câncer.

CAPÍTULO I

REVISÃO DA LITERATURA

1. Câncer

Conceito e epidemiologia

O câncer é caracterizado pela formação e pelo crescimento anormal de células e podem invadir partes adjacentes do corpo e se espalhar para outros órgãos, afetando as funções vitais do organismo (1). O processo de formação de um tumor maligno é o resultado de uma complexa interação entre fatores do hospedeiro, como características genéticas; fatores ambientais, como exposição a substâncias cancerígenas; infecções, como vírus e bactérias; e fatores comportamentais, que envolvem variáveis como alimentação, atividade física, etilismo e tabagismo (2).

O câncer se destaca como o principal obstáculo para o aumento da expectativa de vida da população mundial (3). Segundo o *Global Cancer Statistics* esse cenário é preocupante e foi corroborado pela estimativa mundial de incidência e mortalidade por câncer no último ano de 2020 que estimou em 19,3 milhões de novos casos de câncer em todo o mundo, juntamente com aproximadamente 10 milhões de mortes (4). No Brasil, o câncer é a segunda principal causa de morte prematura, atrás apenas das doenças cardiovasculares (3). A crescente incidência e mortalidade da doença tem causas complexas, mas reflete, sobretudo, o aumento da expectativa de vida e as condições socioeconômicas das populações ao redor do mundo (5). Ainda, em média 60% dos cânceres acometem pessoas com 60 anos ou mais, isso pode ser explicado devido ao envelhecimento da população e ao aumento dos fatores de risco no estilo de vida, como por exemplo: tabagismo, má alimentação e inatividade física (6). Os tipos de cânceres mais prevalentes nesse grupo são o câncer de pulmão, colorretal, melanoma, próstata e mama, em mulheres (7).

Segundo o Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA), estima-se para cada ano do triênio 2023-2025 a ocorrência de 704 mil novos casos

de câncer. Os casos mais incidentes serão o câncer de mama em mulheres (30,1%) e o de próstata em homens (30,0%). Na Região Sul, em mulheres, as três maiores incidências serão os cânceres de mama (27,8%), cólon e reto (10,1%) e traqueia, brônquio e pulmão (8,2%). Já em homens, a incidência maior será o câncer de próstata (20,4%), seguido por tumores de traqueia, brônquio e pulmão (11,6%) e o câncer colorretal ocupará a terceira posição (18,2%). E, no Rio Grande do Sul, a taxa estimada para este mesmo triênio será de 189 mil novos casos, sendo que os tumores de mama (3.720 novos casos) e de próstata (3.510 novos casos) manterão a liderança seguidos do câncer de cólon e reto (3.120 novos casos em homens e mulheres) (7).

2. Desnutrição no paciente idoso com câncer

O câncer ocasiona muitas alterações clínicas nos pacientes, decorrentes tanto do estresse causado pela própria doença quanto do tratamento quimioterápico e radioterápico ao qual são submetidos (8). Algumas das manifestações clínicas apresentadas são perda de peso, náuseas, vômitos, anorexia, diarreia, constipação, alterações no paladar, xerostomia, mucosite, fadiga, entre outras (9).

Pacientes com câncer apresentam alto risco para desnutrição porque tanto as características da doença quanto os efeitos do tratamento antitumoral ameaçam o estado nutricional (10, 11). O risco de desnutrição em pacientes com câncer é maior do que em pacientes que não tem a doença (12). E isso é ainda mais preocupante quando falamos do paciente idoso com câncer. Quanto às características da doença que contribuem para quadros de desnutrição, podemos citar a ativação da inflamação sistêmica que leva a piora da anorexia e do catabolismo, além de

contribuir para a depleção dos estoques de tecido adiposo e para a degradação da massa magra e, conseqüentemente, para a perda de peso corporal (8, 11, 13).

Sobre os tratamentos mais utilizados para o câncer, evidenciam-se o tratamento cirúrgico, quimioterápico e radioterápico. Bem reportados, os efeitos adversos decorrentes do tratamento oncológico clínico (quimioterapia e radioterapia) intensificam o declínio do estado nutricional porque são, em maioria, sintomas que impactam a ingestão de alimentos: náuseas, vômitos e anorexia (14). Por sua vez, a desnutrição pode acentuar ainda mais a toxicidade das terapias, reduzindo a tolerância e a resposta do paciente ao tratamento antineoplásico (13, 15).

Pacientes com câncer apresentam risco elevado de desnutrição. Dados do estudo multicêntrico Inquérito Brasileiro de Avaliação Nutricional (IBRANUTRI), apontam que a desnutrição calórica proteica em pacientes internados por diversas doenças chega a 50% nos hospitais brasileiros. Entre os pacientes oncológicos esse índice chega a 66,4% (16). A desnutrição é ainda mais prevalente em pacientes idosos com câncer, variando de 25% a 85%, uma vez que o processo de envelhecimento está associado às diversas alterações fisiológicas, que podem comprometer o estado nutricional (17, 18). As alterações funcionais naturais do envelhecimento levam a alterações no estado nutricional, incluindo: diminuição das papilas gustativas e do olfato, redução das sensações gustativas e olfativas, diminuição da secreção salivar e gástrica, falha na mastigação (devido à ausência de dentes e/ou próteses mal adaptadas) e constipação. Quando há doenças crônicas, esse processo é ainda mais acelerado (19).

O desenvolvimento e o grau da desnutrição estão relacionados com diversos fatores, tais como, idade do paciente, tipo de câncer, estágio da doença e tipo de tratamento. Estima-se que cerca de 10 a 20% dos óbitos nos pacientes com câncer

possam ser atribuídos à desnutrição e não à doença oncológica (11). Ainda, a desnutrição pode causar desfechos clínicos negativos e prognósticos ruins em pacientes com neoplasias malignas. Entre os desfechos clínicos negativos associados à desnutrição, está a diminuição da resposta ao tratamento oncológico, a redução da qualidade de vida, o aumento de risco para complicações pós-operatórias, aumento do tempo de hospitalização, morbidade e mortalidade (20).

3. Importância da avaliação da nutrição no paciente idoso com câncer

Como apontado anteriormente, o déficit do estado nutricional está estreitamente relacionado com a diminuição da resposta ao tratamento oncológico e da qualidade de vida, com maiores riscos de complicações pós-operatórias, aumento na morbimortalidade, no tempo de internação e no custo hospitalar (21). Desta forma, identificar o risco nutricional neste grupo de pacientes de forma precoce, com o fim de oferecer uma conduta nutricional adequada cujo objetivo é minimizar a desnutrição bem como os efeitos colaterais da terapia se torna de extrema importância e relevância clínica-nutricional (9).

De fato, a avaliação nutricional completa é um dos recursos disponíveis e de fácil aplicabilidade em pacientes com câncer, possibilita reduzir o risco da desnutrição, bem como a síndrome de anorexia-caquexia e as demais manifestações clínicas oriundas da doença e da terapia oncológica (22). A Diretriz Nacional e Internacional, como o Consenso Brasileiro de Nutrição Oncológica da Sociedade Brasileira de Nutrição Oncológica (21) e o *The European Society For Clinical Nutrition* (10), respectivamente, recomendam a utilização de ferramentas de triagem de risco nutricional e de diagnósticos de desnutrição em um período de até 48 horas da internação (10, 21). A partir disso, a avaliação do risco e estado

nutricional do paciente deve ser realizado periodicamente e monitorado para melhor resposta ao tratamento e da intervenção nutricional aplicada (10). Neste sentido, compreender os diferentes tipos instrumentos e, suas especificidades, que podem ser aplicados em distintos grupos de pacientes idosos ou não, é de extrema importância para o sucesso da terapia nutricional. Abaixo apresentaremos as principais ferramentas de triagem e de diagnóstico nutricional. Um quadro resumo dos instrumentos que serão discutidos nesta revisão estão demonstrados na Tabela 1 (Página 30) e Tabela 2 (Página 31).

4. Instrumentos de avaliação de risco nutricional

4.1 Nutritional Risk Screening – 2002 (NRS-2002)

O escore NRS-2002 foi fundamentado em 128 estudos de ensaios clínicos randomizados, realizados com pacientes hospitalizados (23). O rastreamento inicial do risco nutricional desse instrumento é baseado nas variáveis como índice de massa corporal (IMC) $<20,5 \text{ Kg/m}^2$, perda de peso nos últimos três meses, redução na ingestão alimentar na última semana e presença de severidade da doença. Já o rastreamento final é avaliado pela pontuação do estado nutricional e ao aumento das necessidades devido a severidade da doença. A pontuação varia de 0 – 7 pontos, sendo necessário somar 1 ponto quando idade ≥ 70 anos (23). Desta forma, quando a avaliação pontuar ≥ 3 pontos, se classifica como presença de risco nutricional (23).

Estudos prévios vêm demonstrando a associação do alto risco nutricional, avaliado pelo NRS-2002, com desfechos clínicos em diferentes grupos de pacientes (24- 26). Estudo de coorte prospectivo realizado em 260 pacientes idosos (≥ 65 anos) demonstrou que pacientes com risco nutricional (≥ 3 pontos) apresentaram menor chance para alta hospitalar e maior risco ao óbito (24). Esses dados corroboram em

estudo de coorte prospectivo com 375 pacientes adultos críticos, que demonstrou que o risco nutricional pela NRS-2002 (≥ 3 pontos) foi associado com o maior risco de mortalidade (25). Em um estudo transversal realizado em 752 pacientes admitidos em uma Emergência no Brasil, foi demonstrado uma associação positiva e significativa entre o alto risco nutricional, de acordo com a NRS-2002 (≥ 3 pontos) com o maior tempo de permanência hospitalar (aproximadamente 16 dias) e prevalência de mortalidade (26).

Em pacientes oncológicos hospitalizados, a NRS-2002 demonstrou que 32% dos pacientes apresentaram risco nutricional, sendo 18% com escore = 3 e 14% com escore > 3 pontos (27). Estudo prospectivo desenvolvido com 212 pacientes oncológicos hospitalizados mostrou aumento na ingestão alimentar e menor tempo de internação em pacientes que receberam intervenção nutricional após serem classificados como apresentando risco nutricional pela NRS-2002 (28).

Mais recentemente, estudo que avaliou 301 pacientes diagnosticados com câncer colorretal e submetidos à cirurgia, mostrou que o risco nutricional, triado pela NRS-2002, foi um fator de risco independente para complicações pós-operatórias (29). Em pacientes em tratamento combinado de quimioterapia e radioterapia, a NRS-2002 teve um bom desempenho em prever a necessidade de hospitalização, eventos hematológicos adversos e perda de peso. Ainda pacientes em risco nutricional, identificados pela NRS-2002, não finalizaram o tratamento combinado e/ou isolado como a quimioterapia (30).

4.2 Malnutrition Screening Tool (MST)

O MST é um instrumento simples, de fácil e rápida aplicação e pode ser preenchida por qualquer membro da equipe de saúde. Traz questões sobre perda

de peso recente, quantidade de peso perdido e se o paciente apresentou redução da ingesta alimentar por perda do apetite. Pacientes podem apresentar um escore de 0 a 5, aqueles que apresentarem 2 pontos ou mais são classificados com risco nutricional (31).

De acordo com a pesquisa *nutritionDay*, projeto realizado na América Latina, 2 a cada 5 pacientes hospitalizados por diferentes causas estão em risco de desnutrição de acordo com o instrumento MST (32). Em um estudo multicêntrico incluindo 800 pacientes hospitalizados em 4 hospitais da Colômbia, foi demonstrado uma associação positiva e significativa entre risco nutricional, avaliado pelo MST (escore ≥ 2), e maior tempo de hospitalização e maiores taxas de mortalidade (33).

Conforme evidenciado em estudos prévios, em pacientes oncológicos ambulatoriais, o MST é válido, sensível e específico na identificação de desnutrição usando a Avaliação Subjetiva Global Produzida Pelo Paciente (ASG-PPP), ferramenta frequentemente utilizada para avaliar pacientes com câncer (34). Em pacientes idosos com câncer, o risco de desnutrição avaliado pelo MST foi um potencial indicador de mortalidade em 12 meses nos casos em que a quimioterapia foi considerada inviável (35).

4.3 Malnutrition Universal Screening Tool (MUST)

O MUST é uma ferramenta validada em pacientes adultos e é muito utilizada em hospitais e ambulatórios por ser de fácil e rápida aplicação. O escore inclui três parâmetros clínicos: perda de peso, IMC e redução da ingestão alimentar por, pelo menos, cinco dias (36). Os pacientes são categorizados como de baixo risco nutricional se a pontuação for 0 e de risco médio se a pontuação for 1, enquanto uma pontuação de 3 define a desnutrição (36, 37, 38).

Recentemente, um estudo que avaliou 600 pacientes hospitalizados mostrou a associação do MUST com desfechos clínicos desfavoráveis, como tempo de hospitalização prolongado, mortalidade em 6 meses e aumentou o risco de morte intra-hospitalar (39). Em um estudo de coorte prospectiva realizado em pacientes hospitalizados por diferentes causas, mostrou associação entre médio e alto risco nutricional avaliado pelo MUST (escore 1 e escore ≥ 2 , respectivamente) e mortalidade em até 6 meses (40).

Em pacientes com câncer, submetidos à cirurgia, o MUST identificou mais de 83% dos pacientes em risco nutricional e foi preditor de morbidade geral pós-operatória, ocorrência de infecção, tempo de internação e mortalidade no pós-operatório (41). Estes dados estão de acordo com estudo realizado em pacientes que realizaram cirurgia de câncer colorretal, que apresentou associação significativa entre risco nutricional, avaliado pelo MUST, com o tempo de hospitalização >7 dias e aumento do risco do no número de mortes em 3 anos (42). Em um estudo de coorte prospectivo com 80 pacientes oncológicos, mostrou que pacientes com uma pontuação que indica um alto risco nutricional (escore ≥ 2), identificado pela MUST, têm um risco significativamente maior de complicações pós-operatórias após ressecção colorretal em comparação àqueles pacientes que apresentaram baixo risco de desnutrição (43).

4.4 Mini Nutritional Assessment Short Form (MNA-SF)

A MNA foi elaborada especificamente para triar e diagnosticar risco nutricional e desnutrição em pessoas idosas (44, 45). Mais tarde, a MNA na sua forma reduzida foi idealizada para gerar praticidade em comparação à ferramenta completa e com o propósito de triagem nutricional, ela aborda questões sobre diminuição da ingesta

alimentar, perda de peso nos últimos 3 meses, mobilidade reduzida, estresse psicológico, problemas neuropsicológicos, como demência ou depressão, e IMC ou circunferência da panturrilha, caso o cálculo do IMC não seja possível. Pacientes que apresentarem 11 pontos ou menos são classificados com risco nutricional (44).

Estudo realizado com mais de 5.500 pacientes idosos hospitalizados, identificou que 46% dos pacientes estavam desnutridos ou em risco de desnutrição, de acordo com a MNA-SF. Pacientes avaliados com escores entre 0 e 7 foram associados a uma probabilidade seis vezes maior de morte, comparados com pacientes com escore entre 12 e 14 (46). Estudo de coorte prospectivo em 536 idosos hospitalizados (≥ 65 anos), acompanhados por aproximadamente 2,5 anos demonstrou que o risco nutricional, pela MNA-SF, foi preditor para o maior de mortalidade neste grupo de pacientes (46).

Revisão sistemática desenvolvida em pacientes com câncer, avaliou a associação da pontuação da MNA-SF e MNA na sua forma longa, a qual avalia a presença da desnutrição, com diferentes desfechos clínicos, e foi demonstrado que pacientes desnutridos tem menores taxas de sobrevivência e menor qualidade de vida comparado aos pacientes bem nutridos (48). Estudo de coorte e multicêntrico que incluiu 44 instituições do Brasil, utilizou a MNA-SF para avaliar a desnutrição em mais de 3.000 pacientes idosos com câncer hospitalizados. Segundo a MNA-SF, 33.4% dos pacientes estavam desnutridos e 39.3% estavam em risco de desnutrição; e foi encontrada associação positiva e significativa entre desnutrição/risco nutricional e maior tempo de hospitalização (18).

4.5 Avaliação Subjetiva Global – Produzida pelo Próprio Paciente (ASG-PPP) versão reduzida

A ASG-PPP versão reduzida (ASG-PPP SF), parte da ASG-PPP completa, tem recebido mais atenção como uma ferramenta de triagem nutricional válida. Ela compreende as primeiras quatro caixas da versão completa da ferramenta, que abordam questões sobre histórico de peso (pontuação de 0 a 5), ingestão alimentar (pontuação de 0 a 4), sintomas de impacto nutricional (pontuação de 0 a 24) e atividades e função (pontuação 0 a 3) (49). A ferramenta gera uma pontuação de 0 a 36 e os pacientes são categorizados em três grupos baseados no resultado de sua avaliação. São classificados como baixo risco (0 a 3 pontos), médio risco (4 a 8 pontos) e alto risco nutricional (≥ 9 pontos) (28).

Estudos vem demonstrando a associação desta ferramenta com desfechos clínicos em pacientes com câncer hospitalizados e ambulatoriais (34, 50, 51). Estudo transversal que avaliou 443 pacientes hospitalizados com câncer e com outros diagnósticos clínicos mostrou que o tempo de hospitalização de pacientes com alto risco nutricional, segundo a ASG-PPP SF, foi 36% maior em comparação com pacientes com baixo risco nutricional (50). Em pacientes ambulatoriais com câncer e em tratamento quimioterápico, o risco nutricional, segundo a ASG-PPP SF (≥ 5 pontos), foi associado com o maior risco de mortalidade em 1 ano (aproximadamente 3,5 vezes) quando comparado aos pacientes sem risco nutricional (34). Recente estudo de coorte em pacientes oncológicos idosos (mediana de 4,5 anos de acompanhamento) que avaliou o poder prognóstico da ASG-PPP SF na predição da mortalidade demonstrou que a taxa de mortalidade geral para pacientes com risco nutricional (> 5 pontos) foi de 41,1%, e este foi associado de forma positiva e significativa com pior sobrevida global (51).

4.6 Nutritional screening tool score (NUTRISCORE)

O NUTRISCORE foi desenvolvido por um grupo de pesquisa espanhol para detectar risco nutricional em pacientes adultos ambulatoriais com diagnóstico de câncer sólido e hematológico (52). Para a elaboração do instrumento, a MST foi utilizada como base. Além disso, foram adicionadas variáveis sobre a localização do tumor e tratamento, bem como intervalo de tempo específico nas questões referentes a perda de peso e redução da ingestão alimentar (52). O NUTRISCORE consiste em quatro partes: [1] perda de peso involuntária nos últimos 3 meses, [2] redução da ingestão alimentar devido inapetência na última semana, [3] localização do tumor e, [4] tratamento oncológico. A ferramenta foi desenhada para classificar pacientes oncológicos ambulatoriais de acordo com a presença de risco nutricional usando sistema de pontuação (0 a 11 pontos); pacientes que obtiverem ≥ 5 pontos são considerados com risco, enquanto pacientes que obtiverem < 5 são considerados sem risco nutricional (52).

Estudo multicêntrico com pacientes oncológicos hospitalizados, realizado na China, mostrou que apenas 2,9% dos pacientes apresentaram ≥ 5 pontos com a avaliação do NUTRISCORE, enquanto 36,7% dos pacientes estavam em risco nutricional com a avaliação do MST. Quando avaliado o desempenho, utilizando a ASG-PPP como critério referência, o instrumento NUTRISCORE demonstrou sensibilidade mais baixa do que o MST para diagnosticar risco nutricional (53). Outro estudo que avaliou o NUTRISCORE e MUST em pacientes oncológicos hospitalizados, demonstrou que o tempo de hospitalização dos pacientes em risco nutricional avaliados pelo MUST, foi significativamente mais longo que os pacientes avaliados pelo NUTRISCORE (13,3 vs. 7,9 dias; $p < 0,05$) (54).

5. Instrumentos de diagnósticos de desnutrição

5.1 Avaliação Subjetiva Global (ASG)

A ASG foi desenvolvida por Detsky et al. em 1987, com o propósito de não apenas diagnosticar a presença de desnutrição, mas sim identificar aqueles pacientes com maior risco de complicações associadas ao estado nutricional durante sua internação, sendo assim um instrumento tanto prognóstico, como diagnóstico (55). Como critério de referência para o diagnóstico nutricional, a ASG avalia perda de peso, ingestão alimentar, sintomas gastrointestinais e capacidade funcional. Um exame físico também é necessário para avaliar a perda de gordura, perda muscular e retenção de líquidos. Uma classificação A, B ou C indica paciente bem nutrido, moderadamente desnutrido e gravemente desnutrido, respectivamente (55).

Diversos estudos vêm analisando a associação da desnutrição, identificada pela ASG, com desfechos clínicos desfavoráveis (56, 57, 58). Estudo prospectivo em pacientes oncológicos submetidos à cirurgia colorretal demonstrou que desnutrição, identificada pela ASG, se correlacionava positivamente com o maior tempo de hospitalização pós-operatória e taxas gerais de complicações clínicas. Os pacientes bem nutridos (ASG, A) tiveram internações significativamente mais curtas do que aqueles diagnosticados como moderadamente desnutrido e gravemente desnutrido (ASG, B e C) (56, 57). Esses dados corroboram com estudo prévio de coorte prospectivo que avaliou 818 pacientes hospitalizados durante 3 anos. Usando a ASG, 71% dos pacientes foram diagnosticados como bem nutridos e 29% como desnutridos (as categorias moderadamente e severamente foram agrupadas). Os resultados mostraram que os pacientes desnutridos permaneceram no hospital, em média, dois dias a mais e tiveram quase duas vezes mais chances de serem readmitidos em 15 dias após a alta do que os pacientes bem nutridos. Quando

acompanhada por um ano e três anos, a desnutrição aumentou as mortes em quase quatro e três vezes, respectivamente (58).

Em estudo coorte prospectivo que avaliou 234 pacientes com câncer colorretal, pacientes com ASG A (bem nutridos) apresentaram maior tempo de sobrevida que os pacientes com ASG B ou C (desnutrição moderada ou severa), (59). Outro estudo de coorte prospectivo, porém em pacientes com tumores em estágio avançado (III/IV) demonstrou que ~82% dos pacientes apresentaram desnutrição, sendo 56% severamente desnutridos (ASG C). Ainda, foi observado que os pacientes severamente desnutridos, segundo a ASG, apresentaram 2,73 vezes mais chance de ir a óbito em um período de seis meses quando comparados a pacientes bem nutridos (ASG A) (60).

5.2 Avaliação Subjetiva Global – Produzida pelo Próprio Paciente (ASG-PPP)

A partir da ASG, Ottery criou em 1996 uma adaptação específica para a população oncológica: a ASG-produzida pelo próprio paciente (PPP) (22). Esse instrumento é considerado um critério referência para o diagnóstico do estado nutricional em indivíduos com câncer, em razão da avaliação mais direcionada sobre sintomas do tratamento oncológico que causam impacto na nutrição e, na sua sensibilidade na predição de complicações clínicas (61).

Este instrumento é composto por duas partes: [1] uma seção com quatro perguntas a serem respondidas pelo paciente e uma para o profissional de saúde responder. A seção preenchida pelo paciente considera histórico de peso, presença de sintomas relacionados à nutrição, ingestão alimentar e nível de capacidade funcional; [2] as seções preenchidas por um profissional de saúde incluem uma avaliação da demanda metabólica, presença de doença e sua relação com as

necessidades nutricionais, além de elementos do exame físico. Além disso, a ferramenta fornece uma pontuação numérica que orienta o nível de intervenção nutricional necessária, com uma pontuação mais alta indicando maior risco de desnutrição (22). As classificações A, B e C indicam que o paciente está bem nutrido, moderadamente desnutrido e gravemente desnutrido, respectivamente.

Apesar de ser amplamente utilizada em pacientes oncológicos, a ASG-PPP também é usada em diversos outros públicos, como pacientes com tuberculose e em pacientes com AVC. Estudo avaliou a validade da ferramenta em pacientes com tuberculose e demonstrou que pontuações > 6 foram fator de risco para lesões hepáticas e para mortalidade nesses pacientes (62). Outro estudo avaliou a associação da desnutrição, segundo a ASG-PPP, com desfechos desfavoráveis em pacientes hospitalizados com acidente vascular agudo. Em comparação com pacientes bem nutridos, os pacientes desnutridos apresentaram maior tempo de internação (13 vs. 8 dias), aumento de complicações (50% vs. 14%), aumento da frequência de disfagia (71% vs. 32%) e uso de nutrição enteral (93% vs. 59%) (63).

Em 2021, a Sociedade Brasileira de Nutrição Oncológica (SBNO) em sua diretriz recomenda o uso da ASG-PPP como padrão ouro para pacientes oncológicos (21). Em uma revisão sistemática que avaliou 29 estudos em pacientes hospitalizados com câncer (n = 20,441) demonstrou que o ASG-PPP foi um instrumento eficaz para avaliar desfechos clínicos desfavoráveis como tempo de internação prolongada e mortalidade (20). Estudo de coorte que acompanhou por 12 meses mulheres com câncer ginecológico, demonstrou que o maior tempo de hospitalização e as maiores taxas de mortalidade foram observadas em pacientes com desnutrição moderada ou grave, segundo a ASG-PPP, em comparação com pacientes bem nutridas (64). Mais recentemente, em 633 idosos com câncer, estudo

multicêntrico mostrou que pacientes avaliados pela ASG-PPP e com diagnóstico de desnutrição moderada e severa, tiveram 24 vezes mais chance de ter infecções locais e sistêmicas, quando comparados a pacientes bem nutridos (65).

5.3 *Global Leadership Initiative on Malnutrition (GLIM)*

Os critérios para diagnóstico de desnutrição do *Global Leadership Initiative on Malnutrition* (GLIM) foram estabelecidos a partir de um consenso entre representantes das principais sociedades de nutrição clínica globais: *American Society for Parenteral and Enteral Nutrition* (ASPEN), *European Society for Clinical Nutrition and Metabolism* (ESPEN), *Federación Latinoamericana de Terapia Nutricional, Nutrición Clínica y Metabolismo* (FELANPE) e *Parenteral and Enteral Nutrition Society of Asia* (PENSA), ao longo de diversos encontros entre os anos 2016 -2018. O objetivo foi desenvolver critérios globais, baseados em evidência e de fácil aplicação por todos os profissionais de saúde para o diagnóstico de desnutrição em pacientes adultos no cenário clínico (66).

A aplicação dos critérios GLIM é feita em duas etapas. Inicialmente é realizada a triagem nutricional do paciente, utilizando ferramenta validada que mais se adapte ao contexto clínico. Posteriormente é realizada avaliação diagnóstica e classificação da gravidade da desnutrição. Os critérios de classificação da desnutrição são divididos em três fenotípicos (perda de peso não voluntária, índice de massa corporal (IMC) e massa muscular reduzida) e dois etiológicos (ingestão alimentar reduzida e inflamação ou gravidade da doença). Sendo necessária presença de pelo menos um critério fenotípico e um critério etiológico para diagnóstico de desnutrição. Finalmente, os critérios fenotípicos são utilizados para classificação do grau de

desnutrição (66). Mais recentemente, o GLIM discute técnicas de avaliação, em pacientes hospitalizados, da massa muscular nos seus critérios fenotípicos (67).

Os critérios do GLIM foram validados em diferentes grupos. Em pacientes hospitalizados com diferentes diagnósticos clínicos a prevalência da desnutrição, segundo o GLIM foi de 41,6% e este instrumento apresentou validade satisfatória para diagnosticar desnutrição neste grupo de pacientes (68). A presença de desnutrição diagnosticada pela ferramenta foi associada ao risco de mortalidade intra-hospitalar e tempo de hospitalização prolongado (68). Em pacientes com câncer, o GLIM foi uma ferramenta eficaz para avaliar o estado nutricional e prever a sobrevida (12, 69). Além disso, o diagnóstico de desnutrição de acordo com o GLIM foi associado a maiores custos de internação e tempo de internação (70). Já em pacientes idosos com câncer, a desnutrição, usando os critérios GLIM, foi associada a uma taxa de sobrevida diminuída (69).

6. Complementariedade de instrumentos de avaliação nutricional

Estudos recentes têm demonstrado que pode ser mais eficaz e eficiente usar uma combinação de instrumentos para obter uma avaliação mais completa e precisa do risco e do estado nutricional em diferentes grupos de pacientes.

De acordo com estudo em pacientes adultos hospitalizados que avaliou o uso da NRS-2002 e do MUST como ferramenta de risco nutricional para primeira etapa dos critérios GLIM, mostrou que a NRS-2002 é mais precisa em identificar desnutrição que o MUST (71). Isso pode ser explicado pelo fato que há quatro indicadores na ferramenta que estão relacionadas ao GLIM, enquanto somente três indicadores do MUST estariam relacionados aos critérios propostos pelo GLIM (71). Já em pacientes idosos hospitalizados, o instrumento de triagem nutricional MUST

foi considerado superior a NRS-2002 na detecção de desnutrição em pacientes idosos hospitalizados diagnosticados pelos novos critérios GLIM (37).

Um estudo prévio desenvolvido em 705 pacientes com diferentes doenças que avaliou a complementaridade da NRS-2002 com a ASG, demonstrou que a aplicação concomitante destes dois instrumentos pode aumentar a capacidade de prever desfechos clínicos ruins em pacientes hospitalizados (72). Em 384 pacientes criticamente doentes estudo prospectivo demonstrou que a ferramenta, NRS-2002 combinada com o instrumento específico para esta população, o *Nutrition Risk in the Critically ill* (NUTRIC), demonstrou um bom desempenho para prever o desfecho mortalidade hospitalar (73).

Mais recentemente, um estudo longitudinal avaliou a complementaridade das ferramentas de triagem nutricional aos critérios GLIM no diagnóstico de desnutrição em pacientes 601 hospitalizados (39). Neste estudo, em sua maioria oncológicos (53,7%), média de idade de 56 anos e 70,2% submetidos a tratamento cirúrgico, a ferramenta MUST apresentou as maiores métricas de acurácia em comparação com os critérios GLIM e foi um preditor independente de piores desfechos clínicos, como tempo de hospitalização prolongado, readmissão e mortalidade, quando o risco nutricional foi combinado ao diagnóstico de desnutrição (39).

A avaliação do risco e estado nutricional, de forma isolada e concomitante possibilitam identificar os indivíduos que necessitam de intervenção nutricional, para que a terapia possa ser iniciada o mais precocemente possível, a fim de reduzir a gravidade do quadro, auxiliar na evolução do tratamento, aliviar os sintomas e reduzir a morbimortalidade, o diagnóstico correto permite tomar as medidas de intervenção adequadas (74). Contudo, poucos estudos em pacientes com câncer, em especial pacientes idosos, avaliaram a complementariedade de instrumentos de risco

nutricional e ferramentas de diagnóstico de desnutrição e sua capacidade de predição de desfechos clínicos desfavoráveis.

7. Justificativa e objetivos

Pacientes com câncer são frequentemente desnutridos, e a desnutrição está associada à localização, estadiamento do tumor e efeitos adversos da terapia antineoplásica. Em idosos, essa manifestação é mais prevalente em decorrência das alterações biológicas típicas do envelhecimento, aliadas à redução da estrutura musculoesquelética, dos órgãos e dos fluidos corporais (75). Para avaliar o estado nutricional dessa população, vários parâmetros devem ser considerados, incluindo avaliação física, laboratoriais, clínicas, dietéticas e antropométrica (76). A importância de rastrear pacientes com câncer para desnutrição desde o início é bem estabelecida, uma vez que a maioria destes pacientes sofrem uma importante perda de peso e de massa muscular, o que pode limitar a resposta aos tratamentos propostos (8).

Diante dos expostos, em pacientes adultos e idosos com câncer, evidências científicas mostram associação positiva entre alto risco e pior estado nutricional, identificado por diferentes ferramentas, com desfechos clínicos desfavoráveis (33, 58, 65). De fato, estudos vêm descrevendo a importância da avaliação nutricional em pacientes idosos com câncer, onde demonstraram uma associação da desnutrição com maiores taxas de complicações relacionadas ao câncer, maior tempo internação e periodicidade de reinternação hospitalar (46, 65). Instrumentos como a NRS-2002, ASG e ASG-PPP são eficazes para avaliar desfechos clínicos desfavoráveis em pacientes hospitalizados com câncer (20). No entanto, os dados na população idosa com câncer ainda são limitados (77). Ainda, mais recentemente, estudos vêm

descrevendo a importância da associação de distintos instrumentos para complementar a avaliação nutricional em estudos em diferentes grupos de pacientes (39, 72). Até o momento não há estudo que avaliou a complementariedade dos principais instrumentos de risco e de diagnóstico nutricional em pacientes idosos oncológicos hospitalizados.

Neste sentido, considerando que a desnutrição é frequentemente relatada em pacientes idosos com câncer e está associada a piores desfechos clínicos (37) e que estudos sobre a complementariedade neste grupo de indivíduos ainda estão sendo explorados, este estudo teve como objetivos: [1] analisar a complementariedade de cinco instrumentos de risco nutricional (NRS-2002, MST, MUST, MNA-SF e ASG-PPP SF) combinados com três ferramentas de diagnóstico de desnutrição (ASG, ASG-PPP e GLIM) e, [2] a capacidade destes instrumentos, na sua forma isolada e combinada, de prever os desfechos clínicos como tempo de internação prolongada e reinternação em 60 dias em pacientes idosos com câncer.

Tabela 1. Instrumentos comuns de triagem nutricional para pacientes hospitalizados

Instrumento	População	Características do instrumento	Interpretação do resultado
NRS-2002 ²³	Pacientes hospitalizados (adultos e idosos)	Baseada em 2 etapas: (1) IMC < 20,5 kg/m ² , perda de peso nos últimos três meses, redução da ingestão alimentar na semana anterior e presença de doenças graves; (2) cálculo dos escores do estado nutricional e da gravidade da doença. Idade ≥ 70 anos 1 ponto é adicionado ao escore. Considerada o critério referência de triagem nutricional.	<3 sem risco nutricional; ≥3 em risco nutricional.
MST ³¹	Pacientes adultos	Redução de peso e redução do apetite	≥ 2 pontos = risco nutricional
MUST ³⁶	Pacientes adultos	IMC, porcentagem de perda de peso não intencional nos últimos 6 meses e estimativas do efeito da doença na ingestão alimentar	1 ponto = risco nutricional médio ≥ 2 pontos = alto risco nutricional
MNA-SF ^{44,45}	Pacientes idosos	Redução da ingestão alimentar devido perda do apetite, perda de peso nos últimos 3 meses, mobilidade, estresse psicológico, demência ou depressão, IMC ou CP.	12 – 14 pontos = sem risco 8 – 11 pontos = risco nutricional 0 – 7 pontos = desnutrido
ASG-PPP Reduzida ⁴⁹	Pacientes com câncer	Histórico de peso em 1 e 6 meses, ingestão alimentar, sintomas de impacto nutricional, atividade e função <i>(Preenchido pelo Próprio Paciente)</i>	0 – 3 pontos = baixo risco 4 – 8 = médio risco ≥ 9 pontos = alto risco

Abreviações: NRS-2002: *Nutritional Risk Screening-2002*; MST: *Malnutrition Screening Tool*; MUST: *Malnutrition Universal Screening Tool*; MNA-SF: *Mini Nutritional Assessment Short-Form*; ASG-PPP reduzida: Avaliação Subjetiva Global Produzida Pelo Paciente versão reduzida; IMC: Índice de Massa Corporal; CP: Circunferência da Panturrilha.

Tabela 2. Instrumentos comuns de diagnóstico de nutrição para pacientes hospitalizados

Instrumento	População	Características do instrumento	Interpretação do resultado
ASG ⁵⁵	Pacientes adultos e idosos com diferentes contextos clínicos	História clínica (histórico de perda de peso, mudanças na ingestão alimentar, sintomas gastrointestinais persistentes por mais de 2 semanas e capacidade funcional) e exame físico (gordura subcutânea, perda de massa muscular, tornozelo e edema sacral e ascite). Considerado critério referência de diagnóstico de desnutrição.	A = bem nutrido B = moderadamente (ou suspeito de ser) desnutrido C = gravemente desnutrido
ASG-PPP ²²	Pacientes com câncer	Consiste em duas seções: Componentes preenchidos pelo paciente e pelo profissional de saúde. Os componentes preenchidos pelo paciente incluem quatro aspectos: perda de peso, sintomas de impacto nutricional, ingestão de alimentos e capacidade funcional. O componente preenchido pelo profissional de saúde avalia três aspectos (doença e idade, estresse metabólico e exame físico).	A = bem nutrido B = moderadamente (ou suspeito de ser) desnutrido C = gravemente desnutrido
GLIM ⁶⁶	Pacientes adultos e idosos em diferentes contextos clínicos.	Critérios fenotípicos: Perda involuntária de peso corporal, IMC, baixa massa muscular. Critérios etiológicos: baixa ingestão alimentar, doença/inflamação	Após a triagem de desnutrição com ferramenta validada, se um paciente for considerado de risco, dever ser realizada uma avaliação clínica mais abrangente. Para diagnosticar a desnutrição, o consenso GLIM considerou a presença de pelo menos um critério fenotípico e um etiológico. A = bem nutrido B = moderadamente (ou suspeito de ser) desnutrido C = gravemente desnutrido

Abreviações: ASG: Avaliação Subjetiva Global; ASG-PPP: Avaliação Subjetiva Global Produzida Pelo Paciente; GLIM: *Global Leadership Initiative on Malnutrition*

Referências bibliográficas

1. López-Lázaro M. The stem cell division theory of cancer. *Crit Rev Oncol Hematol*. 2018 Mar; 123:95-113. doi: 10.1016/j.critrevonc.2018.01.010
2. Instituto Nacional de Câncer José Alencar Gomes da Silva. Dieta, nutrição, atividade física e câncer: uma perspectiva global: um resumo do terceiro relatório de especialistas com uma perspectiva brasileira / Instituto Nacional de Câncer José Alencar Gomes da Silva. – Rio de Janeiro: INCA, 2020. 140 p. Disponível em <https://www.inca.gov.br/sites/ufu.sti.inca.local/files/media/document/dieta_nutricao_atividade_fisica_e_cancer_resumo_do_terceiro_relatorio_de_especialistas_com_uma_perspectiva_brasileira.pdf> Acesso em: 17 out. 2022.
3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin*. 2021 May;71(3):209-249. doi: 10.3322/caac.21660.
4. Wild CP, Weiderpass E, Stewart BW, editors. *World Cancer Report: Cancer Research for Cancer Prevention*. Lyon, France: International Agency for Research on Cancer, 2020. Disponível em <<http://publications.iarc.fr/586>> Acesso em: 03 jan 2023.
5. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Erratum in: *CA Cancer J Clin*. 2020 Jul;70(4):313.
6. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. *CA Cancer J Clin*. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708.

7. Instituto Nacional de Câncer José Alencar Gomes da Silva. Estimativa 2023: Incidência de câncer no Brasil / Instituto Nacional de Câncer José Alencar Gomes da Silva. – Rio de Janeiro: INCA, 2022. Disponível em <<https://www.gov.br/inca/pt-br/assuntos/cancer/numeros/estimativa>> Acesso em: 23 nov. 2022.
8. Aprile G, Basile D, Giaretta R, Schiavo G, La Verde N, Corradi E, et al. The Clinical Value of Nutritional Care before and during Active Cancer Treatment. *Nutrients*. 2021 Apr 5;13(4):1196. doi: 10.3390/nu13041196.
9. Kuderer NM, Desai A, Lustberg MB, Lyman GH. Mitigating acute chemotherapy-associated adverse events in patients with cancer. *Nat Rev Clin Oncol*. 2022 Nov;19(11):681-697. doi: 10.1038/s41571-022-00685-3.
10. Muscaritoli M, Arends J, Bachmann P, et al. ESPEN practical guideline: Clinical Nutrition in cancer. *Clin Nutr* 2021; 40(5):2898-2913. doi: 10.1016/j.clnu.2021.02.005
11. Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, et al. ESPEN guidelines on nutrition in cancer patients. *Clin Nutr*. 2017 Feb;36(1):11-48. doi: 10.1016/j.clnu.2016.07.015.
12. Zhang Q, Zhang KP, Zhang X, Tang M, Song CH, Cong MH, et al. Scored-GLIM as an effective tool to assess nutrition status and predict survival in patients with cancer. *Clin Nutr*. 2021 Jun;40(6):4225-4233
13. Gomes NS, Maio R. Avaliação Subjetiva Global Produzida pelo Próprio Paciente e Indicadores de Risco Nutricional no Paciente Oncológico em Quimioterapia. *Rev. Bras. Cancerol*. 2015 Set;61(3):235-42. doi: 10.32635/2176-9745.RBC.2015v61n3.253
14. Tsunada K, Saldanha CA, Spexoto MCB. Translation and cultural adaptation to Portuguese of the Nutrition Impact Symptoms scale BRASPEN J 2019; 34(1):52-7.

Disponível em < <http://arquivos.braspen.org/journal/jan-fev-mar-2019/artigos/6-AO-Traducao-e-adaptacao.pdf>> Acesso em: 21 jan 2022.

15. Prado CM, Purcell SA, Laviano A. Nutrition interventions to treat low muscle mass in cancer. *J Cachexia Sarcopenia Muscle*. 2020 Apr;11(2):366-380. doi: 10.1002/jcsm.12525.
16. Waitzberg DL, Caiaffa WT, Correia MI. Hospital malnutrition: the Brazilian national survey (IBRANUTRI): a study of 4000 patients. *Nutrition*. 2001 Jul-Aug;17(7-8):573-80. doi: 10.1016/s0899-9007(01)00573-1.
17. Christner S, Ritt M, Volkert D, Wirth R, Sieber CC, Gaßmann KG. Evaluation of the nutritional status of older hospitalised geriatric patients: a comparative analysis of a Mini Nutritional Assessment (MNA) version and the Nutritional Risk Screening (NRS 2002). *J Hum Nutr Diet*. 2016 Dec;29(6):704-713. doi: 10.1111/jhn.12376.
18. D'Almeida CA, Peres WAF, de Pinho NB, Martucci RB, Rodrigues VD, Ramalho A. Prevalence of Malnutrition in Older Hospitalized Cancer Patients: A Multicenter and Multiregional Study. *J Nutr Health Aging*. 2020;24(2):166-171. doi: 10.1007/s12603-020-1309-4.
19. Isenring E, Elia M. Which screening method is appropriate for older cancer patients at risk for malnutrition? *Nutrition*. 2015 Apr;31(4):594-7. doi: 10.1016/j.nut.2014.12.027.
20. Crestani MS, Grassi T, Steemburgo T. Methods of nutritional assessment and functional capacity in the identification of unfavorable clinical outcomes in hospitalized patients with cancer: a systematic review. *Nutr Rev* 2022; 80:786–811. doi: 10.1093/nutrit/nuab090.
21. Sociedade Brasileira de Nutrição Oncológica. I Consenso brasileiro de nutrição oncológica da SBNO / Sociedade Brasileira de Nutrição Oncológica; organizado por

- Nivaldo Barroso de Pinho. — Rio de Janeiro: Edite, 2021. 164 p. Disponível em <https://www.sbno.com.br/wp-content/uploads/2021/07/consenso_2021.pdf> Acesso em: 13 jan. 2023.
22. Ottery FD. Definition of standardized nutritional assessment and interventional pathways in oncology. *Nutrition*. 1996; 12 (Suppl 1): S15-9. doi: 10.1016/0899-9007(96)90011-8.
23. Kondrup J, Rasmussen HH, Hamberg O, Stanga Z. Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. *Clin Nutr*. 2003; 22(3):321-36. doi:10.1016/S0261-5614(02)00214-5.
24. Sheean PM, Peterson SJ, Chen Y, Liu D, Lateef O, Braunschweig CA. Utilizing multiple methods to classify malnutrition among elderly patients admitted to the medical and surgical intensive care units (ICU). *Clin Nutr*. 2013 Oct;32(5):752-7. doi: 10.1016/j.clnu.2012.12.012.
25. Ceniccola GD, Holanda TP, Pequeno RSF, Mendonça VS, Oliveira ABM, Carvalho LSF, de Brito-Ashurst I, Araújo WMC. Relevance of AND-ASPEN criteria of malnutrition to predict hospital mortality in critically ill patients: A prospective study. *J Crit Care*. 2018 Apr;44:398-403. doi: 10.1016/j.jcrc.2017.12.013.
26. Rabito EI, Marcadenti A, da Silva Fink J, Figueira L, Silva FM. Nutritional Risk Screening 2002, Short Nutritional Assessment Questionnaire, Malnutrition Screening Tool, and Malnutrition Universal Screening Tool Are Good Predictors of Nutrition Risk in an Emergency Service. *Nutr Clin Pract*. 2017 Aug;32(4):526-532. doi: 10.1177/0884533617692527.
27. Bozzetti F, Mariani L, Lo Vullo S; SCRINIO Working Group; Amerio ML, Biffi R, et al. The nutritional risk in oncology: a study of 1,453 cancer outpatients. *Support Care Cancer*. 2012 Aug;20(8):1919-28. doi: 10.1007/s00520-012-1387-x. Erratum in:

- Support Care Cancer. 2012 Aug;20(8):1929. Capuano, Giovanni [corrected to Capuano, Giorgio]
28. Huhmann MB, Cunningham RS. Importance of nutritional screening in treatment of cancer-related weight loss. *Lancet Oncol.* 2005 May;6(5):334-43. doi: 10.1016/s1470-2045(05)70170-4.
29. Xie B, Sun Y, Sun J, Deng T, Jin B, Gao J. Applicability of five nutritional screening tools in Chinese patients undergoing colorectal cancer surgery: a cross-sectional study. *BMJ Open.* 2022 May 27;12(5):e057765. doi: 10.1136/bmjopen-2021-057765
30. Hsueh SW, Lai CC, Hung CY, Lin YC, Lu CH, Yeh KY, et al. A comparison of the MNA-SF, MUST, and NRS-2002 nutritional tools in predicting treatment incompleteness of concurrent chemoradiotherapy in patients with head and neck cancer. *Support Care Cancer.* 2021 Sep;29(9):5455-5462. doi: 10.1007/s00520-021-06140-w.
31. Ferguson M, Capra S, Bauer J, Banks M. Development of a valid and reliable malnutrition screening tool for adult acute hospital patients. *Nutrition.* 1999 Jun;15(6):458-64. doi:10.1016/s0899-9007(99)00084-2
32. Correia MITD, Sulo S, Brunton C, Sulz I, Rodriguez D, Gomez G, et al. Prevalence of malnutrition risk and its association with mortality: nutritionDay Latin America survey results. *Clin Nutr.* 2021 Sep;40(9):5114-5121. doi: 10.1016/j.clnu.2021.07.023.
33. Ruiz AJ, Buitrago G, Rodríguez N, Gómez G, Sulo S, Gómez C, et al. Clinical and economic outcomes associated with malnutrition in hospitalized patients. *Clin Nutr* 2019; 38:1310–6. doi: 10.1016/j.clnu.2018.05.016
34. De Groot LM, Lee G, Ackerie A, van der Meij BS. Malnutrition Screening and Assessment in the Cancer Care Ambulatory Setting: Mortality Predictability and Validity of the Patient-Generated Subjective Global Assessment Short form (PG-SGA

- SF) and the GLIM Criteria. *Nutrients*. 2020 Jul 30;12(8):2287. doi: 10.3390/nu12082287.
35. Botero L, Agarwal E, Berry R, Gillespie K, Isenring E, McCarthy AL. Nutrition risk and mortality in older oncology patients: An exploratory study. *Nutr Diet*. 2020 Sep;77(4):449-455. doi: 10.1111/1747-0080.12547.
36. Elia, M. Screening for malnutrition: a multidisciplinary responsibility. Development and use of the 'Malnutrition Universal Screening Tool' ('MUST') for adults. Malnutrition Advisory Group, a Standing Committee of BAPEN. Redditch: BAPEN (ISBN 1899467 70 X).
37. Bellanti F, Lo Buglio A, Quiete S, Pellegrino G, Dobrakowski M, Kasperczyk A, et al. Comparison of Three Nutritional Screening Tools with the New Glim Criteria for Malnutrition and Association with Sarcopenia in Hospitalized Older Patients. *J Clin Med*. 2020 Jun 17;9(6):1898. doi: 10.3390/jcm9061898.
38. Boléo-Tomé C, Monteiro-Grillo I, Camilo M, Ravasco P. Validation of the Malnutrition Universal Screening Tool (MUST) in cancer. *Br J Nutr*. 2012 Jul;108(2):343-8. doi: 10.1017/S000711451100571X.
39. Lima J, Brizola Dias AJ, Burgel CF, Bernardes S, Gonzalez MC, Silva FM. Complementarity of nutritional screening tools to GLIM criteria on malnutrition diagnosis in hospitalized patients: A secondary analysis of a longitudinal study. *Clin Nutr*. 2022 Oct;41(10):2325-2332. doi: 10.1016/j.clnu.2022.08.022.
40. Gomes-Neto AW, van Vliet IMY, Osté MCJ, de Jong MFC, Bakker SJL, Jager-Wittenaar H, et al. Malnutrition Universal Screening Tool and Patient-Generated Subjective Global Assessment Short Form and their predictive validity in hospitalized patients. *Clin Nutr ESPEN*. 2021 Oct; 45:252-261. doi: 10.1016/j.clnesp.2021.08.015.

41. La Torre M, Ziparo V, Nigri G, Cavallini M, Balducci G, Ramacciato G. Malnutrition and pancreatic surgery: prevalence and outcomes. *J Surg Oncol*. 2013 Jun;107(7):702-8. doi: 10.1002/jso.23304.
42. Almasaudi AS, McSorley ST, Dolan RD, Edwards CA, McMillan DC. The relation between Malnutrition Universal Screening Tool (MUST), computed tomography-derived body composition, systemic inflammation, and clinical outcomes in patients undergoing surgery for colorectal cancer. *Am J Clin Nutr*. 2019 Dec 1;110(6):1327-1334. doi: 10.1093/ajcn/nqz230.
43. van der Kroft G, Bours DMJL, Janssen-Heijnen DM, van Berlo DCLH, Konsten DJLM. Value of sarcopenia assessed by computed tomography for the prediction of postoperative morbidity following oncological colorectal resection: A comparison with the malnutrition screening tool. *Clin Nutr ESPEN*. 2018 Apr;24:114-119. doi: 10.1016/j.clnesp.2018.01.003.
44. Kaiser MJ, Bauer JM, Ramsch C, Uter W, Guigoz Y, Cederholm T et al.; MNA-International Group. Validation of the Mini Nutritional Assessment short-form (MNA-SF): a practical tool for identification of nutritional status. *J Nutr Health Aging*. 2009 Nov;13(9):782-8. doi: 10.1007/s12603-009-0214-7
45. Guigoz Y, Vellas B, Garry PJ. Assessing the nutritional status of the elderly: The Mini Nutritional Assessment as part of the geriatric evaluation. *Nutr Rev*. 1996 Jan;54(1 Pt 2):S59-65. doi: 10.1111/j.1753-4887.1996.tb03793.x.
46. Liu H, Jiao J, Zhu M, Wen X, Jin J, Wang H, et al. Nutritional Status According to the Short-Form Mini Nutritional Assessment (MNA-SF) and Clinical Characteristics as Predictors of Length of Stay, Mortality, and Readmissions Among Older Inpatients in China: A National Study. *Front Nutr*. 2022 Jan 25;9:815578. doi: 10.3389/fnut.2022.815578.

47. Zhang X, Zhang X, Zhu Y, Tao J, Zhang Z, Zhang Y, et al. Predictive Value of Nutritional Risk Screening 2002 and Mini Nutritional Assessment Short Form in Mortality in Chinese Hospitalized Geriatric Patients. *Clin Interv Aging*. 2020 Mar 20;15:441-449. doi: 10.2147/CIA.S244910.
48. Torbahn G, Strauss T, Sieber CC, Kiesswetter E, Volkert D. Nutritional status according to the mini nutritional assessment (MNA)[®] as potential prognostic factor for health and treatment outcomes in patients with cancer - a systematic review. *BMC Cancer*. 2020 Jun 26;20(1):594. doi: 10.1186/s12885-020-07052-4.
49. Jager-Wittenaar H, Ottery FD. Assessing nutritional status in cancer: role of the Patient-Generated Subjective Global Assessment. *Curr Opin Clin Nutr Metab Care*. 2017; 20(5):322-329. doi: 10.1097/MCO.0000000000000389.
50. Dewansingh P, Euwes M, Krijnen WP, Strijbos JH, van der Schans CP, Jager-Wittenaar H. Patient-Generated Subjective Global Assessment Short Form better predicts length of stay than Short Nutritional Assessment Questionnaire. *Nutrition*. 2021 Nov-Dec;91-92:111366. doi: 10.1016/j.nut.2021.111366.
51. Zhang Q, Li XR, Zhang X, Ding JS, Liu T, Qian L, et al. PG-SGA SF in nutrition assessment and survival prediction for elderly patients with cancer. *BMC Geriatr*. 2021 Dec 10;21(1):687. doi: 10.1186/s12877-021-02662-4.
52. Arribas L, Hurtós L, Sendrós MJ, Peiró I, Salleras N, Fort E, et al. NUTRISCORE: A new nutritional screening tool for oncological outpatients. *Nutrition*. 2017 Jan;33:297-303. doi: 10.1016/j.nut.2016.07.015.
53. Kang J, Li H, Shi X, Ma E, Chen W. Validation of the efficacy of the NUTRISCORE for the nutritional screening of cancer patients in China. *BMC Cancer*. 2022 Jan 6;22(1):43. doi: 10.1186/s12885-021-09135-2.

54. Vidal-Casariago A, Amigo-Otero E, Pita-Gutiérrez F, Lugo-Rodríguez G, Almeida-Seoane C, Martínez-Ramonde T. Comparison of MUST and Nutriscore for the Screening of Malnutrition in Hospitalized Oncology Patients. *Nutr Cancer*. 2021;73(10):1941-1946. doi: 10.1080/01635581.2020.1817952.
55. Detsky AS, McLaughlin JR, Baker JP, Johnston N, Whittaker S, Mendelson RA et al. What is subjective global assessment of nutritional status? *JPEN J Parenter Enteral Nutr* 1987; 11(1):8-13. doi: 10.1177/014860718701100108.
56. Lohsiriwat V. The influence of preoperative nutritional status on the outcomes of an enhanced recovery after surgery (ERAS) programme for colorectal cancer surgery. *Tech Coloproctol*. 2014 Nov;18(11):1075-80. doi: 10.1007/s10151-014-1210-4.
57. Gupta A, Gupta E, Hilsden R, Hawel JD, Elnahas AI, Schlachta CM, et al. Preoperative malnutrition in patients with colorectal cancer. *Can J Surg*. 2021 Nov 25;64(6): E621-E629. doi: 10.1503/cjs.016820.
58. Lim SL, Ong KCB, Chan YH, Loke WC, Ferguson M, Daniels L. Malnutrition and its impact on cost of hospitalization, length of stay, readmission and 3-year mortality. *Clin Nutr* 2012; 31:345–50. doi: 10.1016/j.clnu.2011.11.001.
59. Gupta D, Lammersfeld CA, Vashi PG, Burrows J, Lis CG, Grutsch JF. Prognostic significance of Subjective Global Assessment (SGA) in advanced colorectal cancer. *Eur J Clin Nutr*. 2005 Jan;59(1):35-40. doi: 10.1038/sj.ejcn.1602029.
60. Contreras-Bolívar V, Sánchez-Torralvo FJ, Ruiz-Vico M, González-Almendros I, Barrios M, Padín S, et al. GLIM Criteria Using Hand Grip Strength Adequately Predict Six-Month Mortality in Cancer Inpatients. *Nutrients*. 2019 Sep 1;11(9):2043. doi: 10.3390/nu11092043.

61. Santos, AF, Rabelo Junior AA, Campos FLB, Sousa RML, Veloso HJF, Chein MBC. Avaliação Subjetiva Global produzida pelo paciente: tempo de internação e mortalidade em pacientes com câncer. *Rev. Nutri.* 2017 Set;30(5)545-553.
62. Lin HS, Lin MS, Chi CC, Ye JJ, Hsieh CC. Nutrition Assessment and Adverse Outcomes in Hospitalized Patients with Tuberculosis. *J Clin Med.* 2021 Jun 18;10(12):2702. doi: 10.3390/jcm10122702.
63. Martineau J, Bauer JD, Isenring E, Cohen S. Malnutrition determined by the patient-generated subjective global assessment is associated with poor outcomes in acute stroke patients. *Clin Nutr.* 2005 Dec;24(6):1073-7. doi: 10.1016/j.clnu.2005.08.010.
64. Rodrigues CS, Lacerda MS, Chaves GV. Patient Generated Subjective Global Assessment as a prognosis tool in women with gynecologic cancer. *Nutrition.* 2015 Nov-Dec;31(11-12):1372-8. doi: 10.1016/j.nut.2015.06.001.
65. Li W, Yang Y, Li Z, Chen W. Effect of malnutrition and nutritional support to reduce infections in elderly hospitalized patients with cancer: A multicenter survey in China. *Nutrition.* 2023 Feb; 106:111894. doi: 10.1016/j.nut.2022.111894.
66. Cederholm T, Jensen GL, Correia MITD, Gonzalez MC, Fukushima R, Higashiguchi T, et al.; GLIM Core Leadership Committee; GLIM Working Group. GLIM criteria for the diagnosis of malnutrition - A consensus report from the global clinical nutrition community. *Clin Nutr.* 2019 Feb;38(1):1-9. doi: 10.1016/j.clnu.2018.08.002.
67. Compher C, Cederholm T, Correia MITD, Gonzalez MC, Higashiguchi T, Shi HP, et al. Guidance for assessment of the muscle mass phenotypic criterion for the Global Leadership Initiative on Malnutrition diagnosis of malnutrition. *JPEN J Parenter Enteral Nutr.* 2022 Aug;46(6):1232-1242. doi: 10.1002/jpen.2366.
68. Brito JE, Burgel CF, Lima J, Chites VS, Saragiotto CB, Rabito EI, et al. GLIM criteria for malnutrition diagnosis of hospitalized patients presents satisfactory criterion

- validity: A prospective cohort study. *Clin Nutr.* 2021 Jun;40(6):4366-4372. doi: 10.1016/j.clnu.2021.01.009.
69. Zhang X, Tang M, Zhang Q, Zhang KP, Guo ZQ, Xu HX, et al. The GLIM criteria as an effective tool for nutrition assessment and survival prediction in older adult cancer patients. *Clin Nutr.* 2021 Mar;40(3):1224-1232. doi: 10.1016/j.clnu.2020.08.004.
70. Yin L, Lin X, Zhao Z, Li N, He X, Zhang M, et al. Is hand grip strength a necessary supportive index in the phenotypic criteria of the GLIM-based diagnosis of malnutrition in patients with cancer? *Support Care Cancer.* 2021 Jul;29(7):4001-4013. doi: 10.1007/s00520-020-05975-z.
71. Zhang Z, Wan Z, Zhu Y, Zhang L, Zhang L, Wan H. Prevalence of malnutrition comparing NRS2002, MUST, and PG-SGA with the GLIM criteria in adults with cancer: A multi-center study. *Nutrition.* 2021 Mar;83:111072. doi: 10.1016/j.nut.2020.111072.
72. Raslan M, Gonzalez MC, Torrinhas RS, Ravacci GR, Pereira JC, Waitzberg DL. Complementarity of Subjective Global Assessment (SGA) and Nutritional Risk Screening 2002 (NRS 2002) for predicting poor clinical outcomes in hospitalized patients. *Clin Nutr.* 2011 Feb;30(1):49-53. doi: 10.1016/j.clnu.2010.07.002.
73. Machado Dos Reis A, Marchetti J, Forte Dos Santos A, Franzosi OS, Steemburgo T. NUTRIC Score: Isolated and Combined Use With the NRS-2002 to Predict Hospital Mortality in Critically Ill Patients. *JPEN J Parenter Enteral Nutr.* 2020 Sep;44(7):1250-1256. doi: 10.1002/jpen.1804.
74. Duval PA, Vargas BL, Fripp JC, Arrieira IC de O, Lazzeri B, Destri K, et al. Caquexia em Pacientes Oncológicos Internados em um Programa de Internação Domiciliar Interdisciplinar. *Rev. Bras. Cancerol.* 2010 Jun;56(2):207-12.

75. Laur CV, McNicholl T, Valaitis R, Keller HH. Malnutrition or frailty? Overlap and evidence gaps in the diagnosis and treatment of frailty and malnutrition. *Appl Physiol Nutr Metab*. 2017 May;42(5):449-458. doi: 10.1139/apnm-2016-0652.
76. Poziomyck AK, Fruchtenicht AV, Kabke GB, Volkweis BS, Antoniazzi JL, Moreira LF. Reliability of nutritional assessment in patients with gastrointestinal tumors. *Rev Col Bras Cir*. 2016 May-Jun;43(3):189-97. English, Portuguese. doi: 10.1590/0100-69912016003006.
77. Burgel CF, Teixeira PP, Leites GM, Carvalho GD, Modanese PVG, Rabito EI, et al. Concurrent and Predictive Validity of AND-ASPEN Malnutrition Consensus Is Satisfactory in Hospitalized Patients: A Longitudinal Study. *JPEN J Parenter Enteral Nutr* 2021; 45:1061–71. doi: 10.1002/jpen.1980.

CAPÍTULO II

ARTIGO ORIGINAL

Esse artigo foi enviado para publicação na revista *Nutrition*

(FI: 4.893; Qualis A1, Área da Nutrição, CAPES)

Complementarity of nutritional assessment tools to predict prolonged hospital stay and readmission in older patients with solid tumors: a secondary analysis of a cohort study.

Giovanna Potrick Stefani^{a,b}

Mariana Scortegagna Crestani^{a,b}

Laura Machado Scott^{b,c}

Camilla Horn Soares^{b,c}

Thais Steemburgo ^{a,b,c *}

^a Postgraduate Program in Food, Nutrition, and Health, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.

^b Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.

^c Department of Nutrition, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.

Corresponding address: Thais Steemburgo. Postgraduate Program in Food, Nutrition, and Health, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos, 2400, 4º andar, Porto Alegre, Rio Grande do Sul, 90035-003, Brazil. *E-mail address:* tsteemburgo@gmail.com (T. Steemburgo)

Highlights

- To our knowledge, this is the first study to assess the complementarity of five nutritional risk screening tools with three nutritional assessment tools and their ability to predict outcomes in older patients with solid tumors.
- Nutritional Risk Screening 2002 combined with Subjective Global Assessment (SGA) and Malnutrition Screening Tool combined with SGA and Global Leadership Initiative on Malnutrition had the best satisfactory specificity to predict hospitalization.
- The concomitant application of the Mini Nutritional Assessment-Short Form and the Patient-Generated SGA may increase the ability to predict prolonged length of stay and readmission.

Abstract

Objective: To investigate the complementarity of five nutritional risk screening tools (Nutritional Risk Screening 2002 [NRS 2002], Malnutrition Screening Tool [MST], Malnutrition Universal Screening Tool [MUST], Mini Nutritional Assessment-Short Form [MNA-SF], and Patient-Generated Subjective Global Assessment SF [PG-SGA SF]) combined with three malnutrition diagnostic tools (SGA, PG-SGA, and Global Leadership Initiative on Malnutrition [GLIM]) and their ability to predict poor clinical outcomes in older patients with cancer.

Methods: A prospective cohort study was conducted using data collected within 48 hours of hospital admission on nutritional risk (NRS 2002, MST, MUST, MNA-SF, and PG-SGA SF) and presence of malnutrition (SGA, PG-SGA, and GLIM). The patients were grouped according to nutritional risk and malnutrition status. Accuracy tests and logistic regression analysis were used to evaluate the ability of combined tools to predict hospital length of stay (LOS) and readmission.

Results: 248 older patients were evaluated (69.7 ± 7.2 years of age, 59.7% male; 27.4% with gastrointestinal tumor). The median LOS was 4 (3–9) days, and 65.3% of patients remained hospitalized for ≥ 4 days. NRS 2002 combined with SGA and MST combined with SGA and GLIM had the best satisfactory specificity ($> 80\%$) to predict hospitalization. Nutritional risk assessed by MNA-SF and malnutrition by PG-SGA were associated with 2.48- and 6.04-fold increased likelihood of hospitalization (≥ 4 days) and readmission (60 days), respectively.

Conclusion: The concomitant application of MNA-SF (specific for older patients) with PG-SGA (specific for patients with cancer) might enhance the ability to predict LOS and readmission in hospitalized older patients with solid tumors.

Keywords: *Cancer; Malnutrition Complementarity; Nutritional Screening; Nutritional Assessment; Clinical Outcomes.*

Introduction

Cancers such as gastrointestinal and lung are most prevalent in the population aged 60 and over, population aging and the increase in lifestyle risk factors are among the main causes [1]. Furthermore, patients with cancer are at high risk of malnutrition, often associated with the presence of cachexia, sarcopenia, and frailty [2]. In fact, malnutrition is prevalent due to a combination of effects related to disease progression, host response to tumor, and adverse effects of treatment [3]. It is also more common in older patients with solid tumors (~20% – 50%), given that aging is characterized by physiological and body composition changes that result in reduced lean mass and functional capacity [4,5]. This situation can lead to prolonged hospital length of stay (LOS), reduced quality of life, and decreased tolerance to cancer treatment [6].

The American Society for Parenteral and Enteral Nutrition (ASPEN) and the European Society for Clinical Nutrition and Metabolism (ESPEN) recommend screening all patients with cancer for nutritional risk within 48 hours of hospital admission, followed by a comprehensive nutritional assessment if the patient is at high risk of malnutrition [7,8]. The main validated screening tools in hospitalized patients are: (1) Nutritional Risk Screening 2002 (NRS 2002) – designed to include measures of current malnutrition as well as disease severity [9]; (2) Malnutrition Screening Tool (MST) – one of the most widely used screening tools, it is based on only two questions about weight change and loss of appetite [10]; (3) Malnutrition Universal Screening Tool (MUST) – specifically validated in patients with cancer [11]; (4) Mini Nutritional Assessment – Short Form (MNA-SF) – developed to assess nutritional risk particularly in older patients [12]; and (5) Patient-Generated Subjective Global Assessment SF (PG-SGA SF) – specifically designed for patients with cancer [13]. For a comprehensive nutritional assessment in patients with cancer, it is recommended that one of the following tools be used: SGA – considered the reference method [14]; PG-SGA – adapted from the SGA and developed specifically for individuals with cancer [15]; or the Global Leadership Initiative on Malnutrition (GLIM) – a new framework for diagnosing malnutrition [16].

In adult patients with cancer, scientific evidence shows a positive association of high nutritional risk and poor nutritional status, as identified by different tools, with unfavorable clinical outcomes, such as increased LOS and readmission [17,18]. A recent systematic review including 20,441 individuals showed that tools such as the

NRS 2002, SGA, and PG-SGA are effective in assessing unfavorable clinical outcomes in hospitalized patients with cancer [19]. However, data on the older population with cancer are still limited [20].

The complementarity of nutritional assessment tools has been recently considered in studies of general ward patients [21,22] and intensive care unit patients [23]. A prospective study of 705 adult patients evaluating the complementarity of NRS 2002 and SGA showed that these tools were able to predict unfavorable clinical outcomes [21]. A longitudinal study evaluating the use of five nutritional risk screening tools with GLIM in 601 hospitalized patients (50% with cancer) showed that MUST had the best metrics of accuracy compared with the GLIM criteria, suggesting that MUST can be applied in the first step of the GLIM approach for malnutrition diagnosis [22]. A prospective study of 384 critically ill patients demonstrated that the Nutrition Risk in Critically ill (NUTRIC) and NRS 2002 scores performed similarly in predicting in-hospital mortality [23].

Considering that malnutrition is commonly reported in older patients with cancer and associated with poor clinical outcomes [24] and that studies on the complementarity of nutritional assessment tools in this group of patients are still scarce, the current study aimed to analyze the complementarity of five nutritional risk screening tools (NRS 2002, MST, MUST, MNA-SF, and PG-SGA SF) combined with three malnutrition diagnostic tools (SGA, PG-SGA, and GLIM) and their ability to predict unfavorable clinical outcomes, such as LOS and 60-day readmission, in older patients with solid tumors.

Material and methods

Study design and participants

This study is a second part of a cohort study that included patients' adults and older with different types of cancer [25]. Eligible participants were all patients aged ≥ 60 years, of both sexes, with solid tumors who were alert, oriented, speaking coherently, and able to communicate and to undergo anthropometric measurements. Patients in the emergency department or intensive care unit, receiving palliative care, and those with COVID-19 were excluded. The hospital's ethics committee approved the study (protocol number #2019.0708), and all participants included in the study provided written informed consent before data collection. This study was developed

in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement. The patient selection flowchart is shown in **Figure 1**.

Data collection

Data were collected from electronic medical records and at the patient's bedside within the first 48 hours of hospital admission by trained researchers. General and clinical characteristics were collected from the electronic records, including cancer type and stage, treatment, and chronic diseases.

Outcomes

Patients were followed until hospital discharge, and the electronic health records were reviewed to collect data on the outcomes of interest, which included LOS (days), 30-day and 60-day hospital readmission, and 30-day and 60-day in-hospital mortality. LOS was calculated in days from the date of admission to the date of discharge. Prolonged hospitalization was defined as LOS \geq 4 days (the median value was used for this categorization).

Nutritional characteristics

Patients were weighed on hospital admission and asked about weight loss prior to hospitalization at the time of the interview. Body mass index (BMI) was calculated as weight (kg) divided by the square of the height (m²). The percentage of body weight loss was calculated as follows: $([\text{usual body weight} - \text{current body weight}] \times 100 / \text{usual body weight})$, and the result was expressed as a percentage.

Nutritional risk screening

Nutritional risk screening was conducted using five tools: NRS 2002 [9], MST [10], MUST [26], PG-SGA SF [13], and MNA-SF [12].

The NRS 2002 rates patients' nutritional risk according to unintentional weight loss in the last 3 months, reduced food intake, BMI $<$ 20.5 kg/m², disease severity, and age $>$ 70 years, which is considered an additional risk factor. The MST considers recent unintentional weight loss, amount of weight loss (kg), and reduced food intake due to decreased appetite. The MUST considers BMI $<$ 20 kg/m², involuntary weight loss in the last 3 to 6 months, and disease impact on food intake. The PG-SGA SF, the abbreviated version of the PG-SGA and therefore used as a nutritional risk

screening tool, is completed by the patient and provides information on weight in the last 6 months, food intake, nutrition impact symptoms, and functional capacity. Finally, the MNA-SF is a specific tool for older patients that includes reduced food intake and amount of weight loss (kg) in the last 3 months, limited mobility, psychological stress or acute disease, neuropsychological problems, and BMI < 23 kg/m² or calf circumference (CC) < 31 cm as an alternative measure. The following cutoff scores were considered to indicate nutritional risk: NRS 2002 \geq 3 [9], MST \geq 2 [10], MUST \geq 1 [26], PG-SGA SF \geq 4 [27], and MNA-SF \leq 11 [28]. Supplementary Table S1 presents the main characteristics of each nutritional risk screening tool.

Malnutrition diagnosis

Malnutrition diagnosis was made using three tools: SGA [14], PG-SGA [15], and GLIM criteria [16].

The SGA is considered the reference method for nutritional assessment and classifies patients based on weight loss in the last 6 months, reduced food intake, gastrointestinal symptoms, functional capacity, metabolic demand, and muscle wasting and loss of subcutaneous fat. Patients were assigned a rating of A, B, or C indicating well-nourished, moderately malnourished or suspected malnutrition, and severely malnourished, respectively [14].

The PG-SGA was adapted from the SGA for specific use in oncology. It relies on the patient-generated components (weight history, food intake, nutrition impact symptoms, and functional capacity) and on the professional component completed by the researchers (diagnosis, age, metabolic stress, and physical examination). Patients were categorized as well-nourished (category A), moderately malnourished or suspected malnutrition (category B), or severely malnourished (category C). Considering nutritional assessment, patients moderately and severely malnourished according to the SGA and PG-SGA were grouped as with malnutrition [15].

The GLIM criteria classify as malnourished the patients who present with the combination of at least one of three phenotypic criteria (weight loss >5% within the past 6 months or >10% beyond 6 months; BMI <20kg/m² if <70 years, or <22kg/m² if >70 years; and low muscle mass by reduced CC \leq 34 cm or \leq 33 cm for men and woman, respectively (adjusted for BMI) [29, 30]; and at least 1 of the 2 etiological criteria: reduced food intake or assimilation, determined by qualitative evaluation based on patients self-reported percent of actual intake (100%, 75%, 50%, 25%, or

0%) compared to their usual intake, in the last two weeks and/or gastrointestinal symptoms that impact food intake or absorption (nausea, vomiting, diarrhea or constipation); and inflammation by disease burden, in this study, all patients classified due to malignant disease [16]. The remaining participants were classified as well-nourished. **Supplementary Table S1** presents the main characteristics of each malnutrition diagnostic tool.

Assessment of muscle mass and function and functional capacity

Muscle function was measured with a hydraulic dynamometer (Jamar®), and patients underwent three consecutive hand grip strength (HGS) tests, in a seated position, with their elbow bent at a 90° angle. The highest of the three measurements was recorded, and low muscle function was defined as HGS ≤ 16 kg for women and HGS ≤ 27 kg for men [31].

Muscle mass was calculated by CC measurement. With the patient standing upright with legs apart, a non-stretchable measuring tape (Cescorf®, Brazil) was used to measure the calf region of greatest prominence. CC values were adjusted for BMI to help remove the confounding effects of adiposity: the measured value was decreased by 3 cm if BMI 25–30 kg/m² or 7 cm if BMI 30–40 kg/m² [29], and the cutoff value for muscle loss was CC ≤ 33 cm for women and CC ≤ 34 cm for men [30].

Functional capacity was evaluated by the Eastern Cooperative Oncology Group – Performance Status (ECOG-PS) scale, which classifies patients into 5 grades: (0) fully active, (1) restricted in physically strenuous activity, (2) capable of all self-care, (3) capable of only limited self-care, and (4) completely incapable of any self-care [32].

Treatment symptoms, nutritional effects, and diet characteristics during hospitalization

The main symptoms of cancer treatment that can have a nutritional impact were identified during history taking by the researchers: changes in appetite, weight loss, xerostomia, nausea, and constipation.

Information about diet characteristics during hospitalization were collected from the patients' electronic medical records and included route for diet administration, supplementation, and main nutritional composition regarding calories and proteins (kg/weight).

Statistical analysis

This study is a second part of a cohort study that included patients adults and elders with different types of cancer admitted to a university hospital [25].

Continuous variables were expressed as mean and standard deviation (SD) or median (p25–p75). Categorical variables were expressed as absolute (n) and relative (%) frequencies. The normality of the data was assessed by the Kolmogorov-Smirnov test.

The complementarity of nutritional assessment tools was evaluated as follows: (1) patients were grouped as either with or without nutritional risk according to each screening tool, and as either with or without malnutrition according to the malnutrition diagnostic tools; (2) we constructed a variable with three categories referring to the complementarity of nutritional risk and malnutrition diagnosis, eg, NRS 2002 combined with SGA, PG-SGA, and GLIM criteria; as a result, 15 combinations were generated between the tools.

Receiver operating characteristic (ROC) curves with a 95% confidence interval (CI), area under the curve (AUC), sensitivity, specificity, and positive and negative predictive values were estimated to evaluate accuracy of the tools, alone or combined, in predicting LOS \geq 4 days and 60-day readmission. Prediction accuracy was classified based on the AUC values as follows: 0.5–0.6 as very poor; 0.6–0.7 as poor; 0.7–0.8 as moderate; 0.8–0.9 as good; and > 0.9 as excellent [33]. In addition, sensitivity and specificity values $> 80\%$ indicated satisfactory concurrent validity [34].

Logistic regression models were developed considering prolonged hospitalization (LOS \geq 4 days) and readmission (60 days) as the dependent variables to calculate odds ratio (OR) and respective 95% CIs in order to investigate the association of the tools, alone or combined, with clinical outcomes in hospitalized older patients with cancer. All models were adjusted for age, sex, type of cancer, presence of metastasis, and chronic diseases.

Data were analyzed using MedCalc Software (version 20.116) and IBM SPSS (version 25.0). A *P* value of < 0.05 was considered statistically significant.

Results

General and clinical characteristics and clinical outcomes

A total of 248 hospitalized older patients with solid tumors were included in the study, and their general and clinical characteristics are described in **Table 1**. Mean patient age was 69.7 (SD, 7.2) years, 59.7% were male (n = 148), 89.5% were white (n = 221), and 60.1% had ≤ 8 years of schooling (n = 149). Regarding patients' lifestyle, 52% were smokers and 75% were physically inactive. The most common types of cancer were those of the gastrointestinal tract (27.4%), head and neck (16.9%), liver (8.9%), and lung (7.7%). Other types accounted for 39.1% and included bladder cancer, gynecologic cancer, breast cancer, skin cancer, prostate cancer, kidney cancer, and sarcoma. Regarding cancer treatment, 60.9% of patients underwent surgery, 4.8% received chemotherapy, 1.6% received radiotherapy, and 16.9% received combined treatment (surgery, chemotherapy, and/or radiotherapy). Also, 22.2% of patients were diagnosed with advanced cancer (stage III/IV) and 22.6% had metastatic tumors. As for comorbidities, 62% of patients had hypertension, 24.6% had diabetes, and 16.5% had cardiovascular disease.

Regarding clinical outcomes, patients had a median LOS of 4 (3–9) days, 65.3% remained hospitalized for ≥ 4 days, and 14.1% and 10.3% were readmitted within 30 and 60 days, respectively. The overall in-hospital mortality rate was approximately 2.0%.

Nutritional characteristics

Table 2 describes nutritional characteristics. Mean patient weight was 71.9 (SD, 15.6) kg and BMI was 26.4 (SD, 4.8) kg/m²; 16.9% (n = 42) were malnourished, 44.4% (n = 110) were overweight, and 45.6% (n = 90) had weight loss $> 5\%$ in the last 3 months.

A high nutritional risk was observed in 38.7% of patients by NRS 2002, 34.7% by MST, 53.6% by MUST, 66.9% by PG-SGA SF, and 71.0% by MNA-SF. Malnutrition was identified in 52.4% of patients (n = 130) by SGA, 84.7% (n = 210) by PG-SGA, and 72.6% (n = 180) by the GLIM criteria. **Figure 2** shows the prevalence of nutritional risk and malnutrition according to the different assessment tools.

Regarding muscle mass and function, 43.2% of male patients had low HGS and 60.1% had reduced CC. Among women, 66.0% had low HGS and 59.0% had reduced CC. In addition, 15.3% of patients had limited functional capacity, as identified by ECOG-PS (score ≥ 3).

The most common symptoms of cancer treatment that could have a nutritional impact on patients were changes in appetite (31.5%), xerostomia (29.0%), loss of appetite (25.4%), nausea (19.0%), and constipation (16.9%). Regarding diet characteristics during hospitalization, 87.8% of patients received oral nutrition, 70.9% had a regular diet prescription, and 4.1% used nutritional supplements. Only 6.5% of patients received enteral nutrition and 0.8% received oral and enteral nutrition. The mean prescribed energy intake was 27.9 (SD, 9.4) kcal/kg, and the median prescribed protein intake was 1.3 (1.0–1.5) g/kg/day.

Complementarity of nutritional assessment tools for prediction of clinical outcomes

Table 3 shows the accuracy of nutritional risk screening tools alone and combined with malnutrition diagnostic tools in predicting hospitalization (**Figure 3**) and readmission (**Figure 4**). All tools, alone or combined, performed similarly in predicting hospitalization (LOS \geq 4 days) and readmission (60 days). However, NRS 2002 combined with SGA as well as MST combined with SGA and GLIM had the best satisfactory specificity ($> 80\%$) to predict hospitalization. Regarding 60-day readmission, all tools, alone or combined, had high negative predictive values ($> 90\%$); the MNA-SF alone and in combination with the PG-SGA showed the highest sensitivity (92%). **Supplementary Table S3** summarizes the best specificity and sensitivity values of the tools to predict outcomes.

Association of nutritional risk assessed by five screening tools and malnutrition assessed by three diagnostic tools with clinical outcomes

According to the logistic regression model (**Table 4**) adjusted for age, sex, type of cancer, presence of metastasis, and comorbidities, nutritional risk assessed by NRS 2002 in combination with malnutrition assessed by SGA, PG-SGA, and GLIM was positively associated with LOS \geq 4 days. A high nutritional risk according to the MST combined with PG-SGA and GLIM was associated with an approximately 2.1-fold increased likelihood of hospitalization. The MUST alone and combined with the PG-SGA also had a positive and significant association with hospitalization. The MNA-SF (specific for older patients) combined with SGA (reference method) and PG-SGA (recommended for patients with cancer) showed the strongest associations. In fact, nutritional risk assessed by MNA-SF and malnutrition by PG-SGA were

associated with 2.48- and 6.04-fold increased likelihood of hospitalization (LOS \geq 4 days) and readmission (60 days), respectively.

Discussion

To our knowledge, this is the first study to assess the complementarity of five nutritional risk screening tools (NRS 2002, MST, MUST, PG-SGA SF, and MNA SF) with three nutritional assessment tools (SGA, PG-SGA, and GLIM criteria) and their ability to predict LOS and readmission in hospitalized older patients with solid tumors.

The current study demonstrated that NRS 2002 combined with SGA as well as MST combined with SGA and GLIM had the best satisfactory specificity ($> 80\%$) to predict hospitalization. Nevertheless, according to the logistic regression analysis, MNA-SF (specific for older patients) combined with SGA (reference method) and PG-SGA (recommended for patients with cancer) showed the strongest associations with poor clinical outcomes: hospital LOS \geq 4 days and 60-day readmission.

Prevalence of nutritional risk

The prevalence of nutritional risk as assessed by five screening tools ranged from 34.7% (MST) to 71.0% (MNA-SF). The rate of nutritional risk in hospitalized patients described in previous studies ranges from 15.4% to 81.7% [35,36]. In our study, the MNA-SF was the tool that best identified nutritional risk and it is specific for older patients. Similar data have been reported in studies of hospitalized patients with and without cancer [4,37]. An observational study of 2970 hospitalized patients (mean age, 55 years) showed a nutritional risk assessed by MNA-SF of 60.5% [37]. In 3061 older patients with cancer (aged \geq 65 years), nutritional risk assessed by MNA-SF was approximately 73% [4]. The PG-SGA SF was the second tool that best identified the presence of nutritional risk ($\sim 67\%$ of patients). This tool is specific for patients with cancer and assesses the signs and symptoms that can have a nutritional impact [13]. A cohort study evaluating nutritional risk in older patients with cancer reported that 31.5% of patients were considered malnourished according to the PG-SGA SF and that high nutritional risk was associated with the presence of metastasis, reporting loss of appetite and nausea as the most frequent nutrition impact symptoms [38]. In our study, approximately 22% of patients were diagnosed with tumor stage III/IV and metastasis, with loss of appetite (31.5%) and nausea (19%) also being observed in our group of older patients.

Prevalence of malnutrition

In the current study, the presence of malnutrition was assessed by three tools: SGA, PG-SGA, and GLIM criteria, with the highest rate of malnutrition being identified by PG-SGA. The SGA is considered the reference method and evaluates patients based on clinical history (history of weight loss, changes in dietary intake, gastrointestinal symptoms persisting for >2 weeks, and functional capacity) and physical examination (loss of subcutaneous fat, muscle wasting, ankle edema, sacral edema, and ascites) [14]. In our sample, the SGA identified 52.4% of older patients as malnourished. Studies of hospitalized patients without cancer have reported a prevalence of malnutrition, assessed by SGA, ranging from 33.9% [39] to 39% [21]. Among patients with cancer, particularly those with advanced cancer (stage III/IV), the malnutrition rate is as high as 81.6% according to the SGA [40]. The PG-SGA is specifically designed for patients with cancer and relies on patient history (weight history, dietary intake, nutrition impact symptoms, physical function, and metabolic stress) and physical assessment (body fat, muscle mass, and fluid retention) [15]. Studies using the PG-SGA have demonstrated the presence of malnutrition in adult patients and older patients with cancer [35,36,40–42]. According to the PG-SGA classification, 42.5% and 43% of older and adult patients with cancer were considered malnourished at the time of hospital admission [35,36,40]. In women with gynecologic cancer, the prevalence of malnutrition was 62.4% by PG-SGA [41]. In a sample of 3777 adult patients with different types of cancer, 63.7% were classified as malnourished by PG-SGA [42]. In the current study, the high rate of malnutrition (~85%) identified by PG-SGA among our patients with cancer may have been influenced by the main types of cancer (gastrointestinal and head and neck cancer), which have an important impact on nutrition, and by the presence of symptoms of cancer treatment that have an impact on food intake, such as loss of appetite (31.5%) and xerostomia (29%). PG-SGA is specifically designed for patients with cancer, and its scores are strongly affected by treatment symptoms: scores increase with the presence of xerostomia, inappetence, odynophagia, or dysphagia [15]. Finally, according to the GLIM criteria, the prevalence of malnutrition was 72.6% in our sample. A prospective study of patients with cancer reported malnutrition rates similar to ours but varying according to the tool used to assess muscle mass, with values of 72.2% using mid-arm circumference, 77.6% using fat-free mass index, and 80% using HGS [40]. The measures to assess muscle mass and function recommended

by the GLIM are particularly important and can improve the diagnosis of malnutrition. Most older patients in our sample, regardless of sex, had low CC and HGS values. In previous studies of adults and older people with cancer, malnutrition was diagnosed in approximately half of these individuals by the GLIM criteria [6,42].

Complementarity of nutritional assessment tools

Studies evaluating the complementarity of nutritional risk screening tools and malnutrition diagnostic tools are still scarce, especially in older patients with cancer. In our study, NRS 2002 combined with SGA as well as MST combined with SGA and GLIM had the best satisfactory specificity (> 80%) to predict hospitalization. Also, MNA-SF alone and in combination with PG-SGA showed the highest sensitivity (92%) in predicting 60-day readmission. Some of these results are consistent with those of previous [21] and more recent studies [22,24,36]. A previous study demonstrated that the concomitant application of SGA in patients at high nutritional risk detected by the NRS 2002 was associated with an increased ability to predict poor clinical outcomes in hospitalized patients [21]. A multicenter observational study showed that NRS 2002 was better correlated with the GLIM criteria in adults with cancer and could be a good candidate for the first-step malnutrition risk screening according to the GLIM diagnostic scheme [36]. More recently, a longitudinal study of 601 hospitalized adult patients, most with cancer (53.7%) and undergoing surgical treatment (70.2%), showed that MUST had the best metrics of accuracy, sensitivity, and specificity with the GLIM criteria, followed by MST [22]. In our study, all included patients had cancer and approximately 61% were treated surgically during hospitalization, but MUST (alone or combined) did not show good accuracy in predicting the clinical outcomes. However, MST with GLIM showed a specificity > 80%. Conversely, MUST performed better than SGA and NRS 2002 in detecting malnutrition in hospitalized older patients diagnosed by the new GLIM criteria [24].

Association between malnutrition and clinical outcomes in hospitalized older patients with cancer

Regarding the association of nutritional risk (assessed by five screening tools) and malnutrition (assessed by three nutritional assessment tools) with clinical outcomes, we observed that the combination of MNA-SF and PG-SGA yielded the best results, identifying an increased likelihood of hospital LOS \geq 4 days (2.48 times)

and 60-day hospital readmission (6.04 times). These are interesting and robust results, since our sample consisted of older patients with cancer and these tools are widely recommended and used in clinical practice, although alone.

In adult patients without cancer, nutritional risk (NRS 2002) combined with malnutrition (SGA) predicted a significantly increased probability of complications, and this combination was the most suitable one for detecting patients with a probability of unfavorable clinical outcomes [21]. Our results showed a 2.23-fold increased likelihood of hospital LOS ≥ 4 days for patients classified as malnourished by the combination of NRS 2002 and SGA, but the results were not significant for 60-day hospital readmission.

Among hospitalized patients, regardless of diagnosis, application of the MUST or MST in combination with the GLIM criteria increased the likelihood of LOS, in-hospital mortality, 6-month mortality, and hospital readmission, added to the adequate sensitivity, specificity, and accuracy of MUST to identify patients diagnosed as malnourished by the GLIM [22]. In this respect, the authors recommended the combination of MUST with GLIM to assess malnutrition in hospitalized patients [22]. Our results did not demonstrate a significant association between MUST combined with GLIM and LOS or readmission, but the MUST was positively associated with prediction of LOS ≥ 4 days when used alone or in combination with PG-SGA ($P < 0.05$).

Implications for clinical practice

Our findings suggest that MNA-SF combined with PG-SGA is a good option for a comprehensive and individualized nutritional assessment in older patients with cancer. Moreover, the complementarity between nutritional risk screening and malnutrition diagnosis is essential to avoid misclassification. Validated tools are critical for early detection of nutritional risk and status, enabling a specialized nutritional intervention [3,7,8]. Immediate nutritional screening helps reduce mortality, improve quality of life, and reduce hospital costs, mainly because the hospital LOS of malnourished patients is almost twice as long as that of well-nourished patients [3, 5].

According to the 2021 ESPEN guideline, MNA-SF is the most suitable tool to screen older patients for malnutrition and has been widely used in different healthcare settings [3]. The MNA-SF can also quickly detect frailer patients with cancer and

malnutrition [43]. The PG-SGA is one of the few tools that cover all aspects that can cause malnutrition and one of the most comprehensive tools for the assessment of nutrition impact symptoms, and for this reason it is considered a reference tool in patients with cancer [44]. In this respect, combining these two tools permits more effective evaluation, since they complement each other. For example, MNA-SF with PG-SGA can recover weight information from the last 6 months and both tools assess food intake, while the PG-SGA provides complementary data such as diet consistency and use or not of supplements. In our study, 70.9% of patients had a regular diet prescription and only 4.1% used nutritional supplements. The PG-SGA also evaluates the main symptoms that can have a nutritional impact, which is an important factor given that patients with cancer undergoing treatment have a high prevalence of symptoms such as loss of appetite, nausea, vomiting, diarrhea, and constipation [44]. Additionally, MNA-SF evaluates CC as a measure of muscle mass, which is lacking in the PG-SGA. More recently, the assessment of CC has been widely encouraged to monitor loss of muscle mass in hospitalized patients with and without cancer [45].

Our study has some limitations, such as heterogeneity of the study sample. Also, all types of solid tumors were included, but these effects were minimized by adjusting the logistic regression analyses for type of cancer, age, sex, presence of metastasis, and chronic diseases. In fact, 44.3% of our patients had gastrointestinal or head and neck cancer, and both tumors are closely associated with malnutrition due to the combination of effects related to disease progression, host response to tumor, and, particularly in gastrointestinal cancer, to the direct effect of mechanical obstruction by the tumor, with consequent malabsorption of nutrients [46].

Nevertheless, this study provides important data on the complementarity of the various tools currently used for nutritional assessment, as well as their performance and associations for the prediction of clinical outcomes in hospitalized older patients with different types of cancer.

Conclusion

In hospitalized older patients with solid tumors, the concomitant application of MNA-SF (specific for older patients) and PG-SGA (specific for patients with cancer) predicted hospital LOS and hospital readmission, and it is an appropriate combination to evaluate these patients.

Financial support

This study was supported by Fundo de Incentivo a Pesquisa (FIPE) of the Hospital de Clínicas de Porto Alegre, Brazil. This study was also financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) – Finance Code 001. Giovanna P. Stefani and Mariana S. Crestani received a CAPES scholarship. Laura M. Scott received a scholarship from Universidade Federal do Rio Grande do Sul.

Authorship

TS and GPS conceived and designed the study. MSC, GPS, LMS, and CHS contributed to data acquisition. GPS and TS participated in the analysis and interpretation of the data. GPS, MSC, and TS drafted the initial manuscript. All authors critically revised the manuscript and approved the final version. TS is the guarantor and attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Conflict of interest

The authors declare no conflicts of interest.

Acknowledgements

The authors thank the volunteers and investigating staff. Also, the authors thank Professor Stela Castro for helping improve the statistical analysis of the data.

References

- [1] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. *CA Cancer J Clin.* 2022;72(1):7-33. <https://doi.org/10.3322/caac.21708>
- [2] Arends J, Strasser F, Gonella S, et al. Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines☆. *ESMO Open.* 2021;6(3):100092. <https://doi.org/10.1016/j.esmoop.2021.100092>
- [3] Muscaritoli M, Arends J, Bachmann P, et al. ESPEN practical guideline: Clinical Nutrition in cancer. *Clin Nutr.* 2021;40(5):2898-2913. doi:10.1016/j.clnu.2021.02.005. <https://doi.org/10.1016/j.clnu.2021.02.005>
- [4] D'Almeida CA, Peres WAF, de Pinho NB, Martucci RB, Rodrigues VD, Ramalho A. Prevalence of Malnutrition in Older Hospitalized Cancer Patients: A Multicenter and Multiregional Study. *J Nutr Health Aging.* 2020;24(2):166-171. <https://doi.org/10.1007/s12603-020-1309-4>
- [5] Laur CV, McNicholl T, Valaitis R, Keller HH. Malnutrition or frailty? Overlap and evidence gaps in the diagnosis and treatment of frailty and malnutrition. *Appl Physiol Nutr Metab.* 2017;42(5):449-458. <https://doi.org/10.1139/apnm-2016-0652>
- [6] Zhang X, Tang M, Zhang Q, et al. The GLIM criteria as an effective tool for nutrition assessment and survival prediction in older adult cancer patients. *Clin Nutr.* 2021;40(3):1224-1232. <https://doi.org/10.1016/j.clnu.2020.08.004>
- [7] Arends J, Bachmann P, Baracos V, et al. ESPEN guidelines on nutrition in cancer patients. *Clin Nutr.* 2017;36(1):11-48. <https://doi.org/10.1016/j.clnu.2016.07.015>
- [8] Thompson KL, Elliott L, Fuchs-Tarlovsky V, Levin RM, Voss AC, Piemonte T. Oncology Evidence-Based Nutrition Practice Guideline for Adults. *J Acad Nutr Diet.* 2017;117(2):297-310.e47. <https://doi.org/10.1016/j.jand.2016.05.010>.
- [9] Kondrup J, Rasmussen HH, Hamberg O, Stanga Z; Ad Hoc ESPEN Working Group. Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. *Clin Nutr.* 2003;22(3):321-336. [https://doi.org/10.1016/S0261-5614\(02\)00214-5](https://doi.org/10.1016/S0261-5614(02)00214-5).
- [10] Ferguson M, Capra S, Bauer J, Banks M. Development of a valid and reliable

malnutrition screening tool for adult acute hospital patients. *Nutrition*. 1999;15(6):458-464. [https://doi.org/10.1016/s0899-9007\(99\)00084-2](https://doi.org/10.1016/s0899-9007(99)00084-2).

[11] Boléo-Tomé C, Monteiro-Grillo I, Camilo M, Ravasco P. Validation of the Malnutrition Universal Screening Tool (MUST) in cancer. *Br J Nutr*. 2012;108(2):343-348. <https://doi.org/10.1017/S000711451100571X>.

[12] Guigoz Y, Vellas B, Garry PJ. Assessing the nutritional status of the elderly: The Mini Nutritional Assessment as part of the geriatric evaluation. *Nutr Rev*. 1996;54(1 Pt 2):S59-S65. <https://doi.org/10.1111/j.1753-4887.1996.tb03793.x>.

[13] Jager-Wittenaar H, Ottery FD. Assessing nutritional status in cancer: role of the Patient-Generated Subjective Global Assessment. *Curr Opin Clin Nutr Metab Care*. 2017;20(5):322-329. <https://doi.org/10.1097/MCO.0000000000000389>.

[14] Detsky AS, McLaughlin JR, Baker JP, et al. What is subjective global assessment of nutritional status?. *JPEN J Parenter Enteral Nutr*. 1987;11(1):8-13. <https://doi.org/10.1177/014860718701100108>.

[15] Ottery FD. Definition of standardized nutritional assessment and interventional pathways in oncology. *Nutrition*. 1996;12(1 Suppl):S15-S19. [https://doi.org/10.1016/0899-9007\(96\)90011-8](https://doi.org/10.1016/0899-9007(96)90011-8).

[16] Cederholm T, Jensen GL, Correia MITD, et al. GLIM criteria for the diagnosis of malnutrition - A consensus report from the global clinical nutrition community. *Clin Nutr*. 2019;38(1):1-9. <https://doi.org/10.1016/j.clnu.2018.08.002>.

[17] Lim SL, Ong KC, Chan YH, Loke WC, Ferguson M, Daniels L. Malnutrition and its impact on cost of hospitalization, length of stay, readmission and 3-year mortality. *Clin Nutr*. 2012;31(3):345-350. <https://doi.org/10.1016/j.clnu.2011.11.001>.

[18] Ruiz AJ, Buitrago G, Rodríguez N, et al. Clinical and economic outcomes associated with malnutrition in hospitalized patients. *Clin Nutr*. 2019;38(3):1310-1316. <https://doi.org/10.1016/j.clnu.2018.05.016>.

[19] Crestani MS, Grassi T, Steemburgo T. Methods of nutritional assessment and functional capacity in the identification of unfavorable clinical outcomes in hospitalized patients with cancer: a systematic review. *Nutr Rev*. 2022;80(4):786-811. <https://doi.org/10.1093/nutrit/nuab090>.

- [20] Burgel CF, Teixeira PP, Leites GM, et al. Concurrent and Predictive Validity of AND-ASPEN Malnutrition Consensus Is Satisfactory in Hospitalized Patients: A Longitudinal Study. *JPEN J Parenter Enteral Nutr.* 2021;45(5):1061-1071. <https://doi.org/10.1002/jpen.1980>.
- [21] Raslan M, Gonzalez MC, Dias MC, et al. Comparison of nutritional risk screening tools for predicting clinical outcomes in hospitalized patients. *Nutrition.* 2010;26(7-8):721-726. <https://doi.org/10.1016/j.nut.2009.07.010>.
- [22] Lima J, Brizola Dias AJ, Burgel CF, Bernardes S, Gonzalez MC, Silva FM. Complementarity of nutritional screening tools to GLIM criteria on malnutrition diagnosis in hospitalised patients: A secondary analysis of a longitudinal study. *Clin Nutr.* 2022;41(10):2325-2332. <https://doi.org/10.1016/j.clnu.2022.08.022>.
- [23] Machado Dos Reis A, Marchetti J, Forte Dos Santos A, Franzosi OS, Steemburgo T. NUTRIC Score: Isolated and Combined Use With the NRS-2002 to Predict Hospital Mortality in Critically Ill Patients. *JPEN J Parenter Enteral Nutr.* 2020;44(7):1250-1256. <https://doi.org/10.1002/jpen.1804>.
- [24] Bellanti F, Lo Buglio A, Quiete S, et al. Comparison of Three Nutritional Screening Tools with the New Glim Criteria for Malnutrition and Association with Sarcopenia in Hospitalized Older Patients. *J Clin Med.* 2020;9(6):1898. <https://doi.org/10.3390/jcm9061898>.
- [25] Crestani MS, Stefani GP, Scott LM, Steemburgo T. Accuracy of the GLIM Criteria and SGA Compared to PG-SGA for the Diagnosis of Malnutrition and Its Impact on Prolonged Hospitalization: A Prospective Study in Patients with Cancer. *Nutr Cancer.* 2023;1-12. <https://doi.org/10.1080/01635581.2023.2184748>
- [26] Elia M. Screening for Malnutrition: A Multidisciplinary Responsibility. Development and Use of the 'Malnutrition Universal Screening Tool' ('MUST') for Adults. Redditch, UK: BAPEN; 2003
- [27] Gabrielson DK, Scaffidi D, Leung E, et al. Use of an abridged scored Patient-Generated Subjective Global Assessment (abPG-SGA) as a nutritional screening tool for cancer patients in an outpatient setting. *Nutr Cancer.* 2013;65(2):234-239. <https://doi.org/10.1080/01635581.2013.755554>.
- [28] Kaiser MJ, Bauer JM, Ramsch C, et al. Validation of the Mini Nutritional

Assessment short-form (MNA-SF): a practical tool for identification of nutritional status. *J Nutr Health Aging*. 2009;13(9):782-788. <https://doi.org/10.1007/s12603-009-0214-7>.

[29] Gonzalez MC, Mehrnezhad A, Razaviarab N, Barbosa-Silva TG, Heymsfield SB. Calf circumference: cutoff values from the NHANES 1999-2006. *Am J Clin Nutr*. 2021;113(6):1679-1687. <https://doi.org/10.1093/ajcn/nqab029>.

[30] Barbosa-Silva TG, Bielemann RM, Gonzalez MC, Menezes AM. Prevalence of sarcopenia among community-dwelling elderly of a medium-sized South American city: results of the COMO VAI? study. *J Cachexia Sarcopenia Muscle*. 2016;7(2):136-143. <https://doi.org/10.1002/jcsm.12049>.

[31] Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. *Age Ageing*. 2019;48(1):16-31. <https://doi.org/10.1093/ageing/afy169>.

[32] Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol* 1982;5:649–55. <https://doi.org/10.1097/00000421-198212000-00014>

[33] Metz CE. Basic principles of ROC analysis. *Semin Nucl Med*. 1978;8(4):283-298. [https://doi.org/10.1016/S0001-2998\(78\)80014-2](https://doi.org/10.1016/S0001-2998(78)80014-2).

[34] de van der Schueren MAE, Keller H; GLIM Consortium, et al. Global Leadership Initiative on Malnutrition (GLIM): Guidance on validation of the operational criteria for the diagnosis of protein-energy malnutrition in adults. *Clin Nutr*. 2020;39(9):2872-2880. <https://doi.org/10.1016/j.clnu.2019.12.022>.

[35] Li W, Yang Y, Li Z, Chen W. Effect of malnutrition and nutritional support to reduce infections in elderly hospitalized patients with cancer: A multicenter survey in China. *Nutrition*. 2023;106:111894. <https://doi.org/10.1016/j.nut.2022.111894>.

[36] Zhang Z, Wan Z, Zhu Y, Zhang L, Zhang L, Wan H. Prevalence of malnutrition comparing NRS2002, MUST, and PG-SGA with the GLIM criteria in adults with cancer: A multi-center study. *Nutrition*. 2021;83:111072. <https://doi.org/10.1016/j.nut.2020.111072>.

[37] Doundoulakis I, Poulia KA, Antza C, et al. Screening for Malnutrition Among

People Accessing Health Services at Greek Public Hospitals: Results From an Observational Multicenter Study. *JPEN J Parenter Enteral Nutr.* 2018;42(4):709-718. <https://doi.org/10.1177/0148607117722748>.

[38] Zhang Q, Li XR, Zhang X, et al. PG-SGA SF in nutrition assessment and survival prediction for elderly patients with cancer. *BMC Geriatr.* 2021;21(1):687. <https://doi.org/10.1186/s12877-021-02662-4>.

[39] Brito JE, Burgel CF, Lima J, et al. GLIM criteria for malnutrition diagnosis of hospitalized patients presents satisfactory criterion validity: A prospective cohort study. *Clin Nutr.* 2021;40(6):4366-4372. <https://doi.org/10.1016/j.clnu.2021.01.009>.

[40] Contreras-Bolívar V, Sánchez-Torralvo FJ, Ruiz-Vico M, et al. GLIM Criteria Using Hand Grip Strength Adequately Predict Six-Month Mortality in Cancer Inpatients. *Nutrients.* 2019;11(9):2043. <https://doi.org/10.3390/nu11092043>.

[41] Rodrigues CS, Lacerda MS, Chaves GV. Patient Generated Subjective Global Assessment as a prognosis tool in women with gynecologic cancer. *Nutrition.* 2015;31(11-12):1372-1378. <https://doi.org/10.1016/j.nut.2015.06.001>.

[42] Zhang KP, Tang M, Fu ZM, et al. Global Leadership Initiative on Malnutrition criteria as a nutrition assessment tool for patients with cancer. *Nutrition.* 2021;91-92:111379. <https://doi.org/10.1016/j.nut.2021.111379>.

[43] Sobrini P, Sánchez-Castellano C, Cruz-Jentoft AJ. MNA-SF as a screening tool for malnutrition diagnosed with the glim criteria in older persons with cancer. *Eur Geriatr Med.* 2021;12(3):653-656. <https://doi.org/10.1007/s41999-020-00442-8>.

[44] de Pinho NB, Martucci RB, Rodrigues VD, et al. Malnutrition associated with nutrition impact symptoms and localization of the disease: Results of a multicentric research on oncological nutrition. *Clin Nutr.* 2019;38(3):1274-1279. <https://doi.org/10.1016/j.clnu.2018.05.010>.

[45] Prado CM, Landi F, Chew STH, et al. Advances in muscle health and nutrition: A toolkit for healthcare professionals. *Clin Nutr.* 2022;41(10):2244-2263. <https://doi.org/10.1016/j.clnu.2022.07.041>.

[46] Aprile G, Basile D, Giaretta R, et al. The Clinical Value of Nutritional Care before and during Active Cancer Treatment. *Nutrients.* 2021;13(4):1196.

[https://doi.org/10.3390/nu13041196.](https://doi.org/10.3390/nu13041196)




Figure 1. Flowchart of patient selection






Figure 2. Prevalence of nutritional risk according to NRS-2002, MST, MUST, PG-SGA SF and malnutrition by SGA, PG-SGA and GLIM criteria in elderly cancer patients.


NRS-2002 = Nutritional Risk Screening; MST = Malnutrition Screening Tool; MUST = Malnutrition Universal Screening Tool; PG-SGA SF = Patient- Generated Subjective Global Assessment Short Form; MNA SF Mini Nutritional Assessment Short Form; SGA = Subjective Global Assessment; PG-SGA = Patient- Generated Subjective Global Assessment; GLIM = Global Leadership Initiative on Malnutrition




3a.




3b.



3c.



3d.



3e.

Figure 3. Receiver operating characteristic (ROC) curves for prediction of hospitalization ≥ 4 days in elderly cancer inpatients. 3a. NRS-2002 isolated and combined; 3b. MST isolated and combined; 3c. MUST isolated and combined; 3d. PG-SGA SF isolated and combined; 3e. MNA-SF isolated and combined.

NRS-2002 = Nutritional Risk Screening; MST = Malnutrition Screening Tool; MUST = Malnutrition Universal Screening Tool; PG-SGA SF = Patient- Generated Subjective Global Assessment Short Form; MNA SF Mini Nutritional Assessment Short Form; SGA = Subjective Global Assessment; PG-SGA = Patient-Generated Subjective Global Assessment; GLIM = Global Leadership Initiative on Malnutrition

Table 1. Characteristics of 248 hospitalized elderly cancer patients:

General	
Age (years)	69.7 ± 7.2
Sex (male)	148 (59.7%)
Race (white)	221 (89.5%)
Education (≤8 years)	149 (60.1%)
Smoking history (yes)	129 (52.0%)
Sedentary lifestyle (yes)	186 (75.0%)
Clinics	
Prevalence	
Gastrointestinal	68 (27.4%)
Head and neck	42 (16.9%)
Liver	22 (8.9%)
Lung	19 (7.7%)
Others*	97 (39.1%)
Treatment	
Surgery	151 (60.9%)
Chemotherapy	12 (4.8%)
Radiotherapy	4 (1.6%)
Combined treatment	42 (16.9%)
Tumor stage III/IV	55 (22.2%)
Presence of metastasis (yes)	56 (22.6%)
Chronic diseases	
Hypertension	153 (61.7%)
Diabetes	61 (24.6%)
Cardiovascular disease	41 (16.5%)
Outcomes	

Length of stay (LOS; days)	4 (3 – 9)
LOS ≥ 4 days	65.3%
Readmission (yes)	
30 days	35 (14.1%)
60 days**	25 (10.3%)
Hospital death (yes)	
30 days	5 (2.0%)
60 days**	4 (1.6%)

Data expressed as mean ± SD, median (p25-p75) or n (%).

*Other cancer included were bladder, gynecological, breast, skin, prostate, kidney and sarcoma.

** n = 243.

Table 2. Nutritional characteristics of 248 hospitalized elderly cancer patients:

	Values
Weight	
Current/on admission (kg)	71.9 ± 15.6
BMI (kg/m ²)	26.4 ± 4.8
Malnourished	42 (16.9%)
Overweight	110 (44.4%)
Weight loss > 5% (3 months)	113 (45.6%)
Nutritional risk	
NRS-2002 (score ≥3)	96 (38.7%)
MST (score ≥ 2)	86 (34.7%)
MUST (score ≥ 1)	133 (53.6%)
PG-SGA SF (score ≥ 4)	166 (66.9%)
MNA SF (score ≤11)	176 (71.0%)
Nutritional status	
SGA (moderately and severely malnourished)	130 (52.4%)
PG-SGA (moderately and severely malnourished)	210 (84.7%)
GLIM (malnourished)	180 (72.6%)
Strength and assessment of muscle mass and functional capacity	
HGS (Kg)*	
Male (low)	64 (43.2%)
Female (low)	66 (66.0%)
CC (cm)**	
Male (low)	89 (60.1%)
Female (low)	59 (59.0%)
ECOG (score ≥ 3)	38 (15.3%)
Treatment symptoms and nutritional effects	

Appetite change (yes)	78 (31.5%)
Xerostomia	72 (29.0%)
Appetite loss	63 (25.4%)
Nausea	47 (19.0%)
Constipation	42 (16.9%)

Diet characteristics during hospitalization

Oral nutrition	216 (87.8%)
Regular diet	173 (70.9%)
Oral and nutritional supplements	10 (4.1%)
Enteral nutrition	16 (6.5%)
Enteral and oral nutrition	2 (0.8%)
Calorie intake (kg/weight)	27.9 ± 9.4
Protein intake (kg/weight)	1.3 (1.0 – 1.5)

Data expressed as mean ± SD, median (p25-p75) or n (%).

BMI = Body Mass Index; NRS-2002 = Nutritional Risk Screening; MST = Malnutrition Screening Tool; MUST = Malnutrition Universal Screening Tool; SGA = Subjective Global Assessment; PG-SGA = Patient- Generated Subjective Global Assessment; PG-SGA SF = Patient- Generated Subjective Global Assessment Short Form; MNA SF Mini Nutritional Assessment Short Form; GLIM = Global Leadership Initiative on Malnutrition; HGS = hand grip strength; CC = calf circumference; ECOG = Eastern Cooperative Oncology Group.

*Low HGS = Male (≤ 27 kg); Female (≤ 16 kg) [27]; ** Low CC: Male (≤ 34 cm); Female (≤ 33 cm) [28]; CC values were adjusted by patient's BMI, in order to help to remove the confounding effects of adiposity [29].

Table 3. Accuracy, sensitivity, specificity, predictive positive and negative values of nutritional assessment tools isolated and combined for prediction of hospitalization (≥ 4 days) and readmission (60 days) in elderly cancer inpatients.

Outcomes / nutritional assessment tools	AUC ROC (CI 95%)	Accuracy (%)	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)
Hospitalization (≥ 4 days)						
<i>NRS-2002 isolated</i>	0.618 (0.546 – 0.690)	57.6	46.91	76.74	79.15	43.45
NRS-2002 and SGA	0.611 (0.539 – 0.683)	55.25	42.00	80.23	79.98	42.36
NRS-2002 and PG-SGA	0.618 (0.546 – 0.690)	57.60	46.91	76.74	79.15	43.45
NRS-2002 and GLIM	0.605 (0.533 – 0.677)	54.85	41.98	79.07	79.05	42.00
<i>MST isolated</i>	0.587 (0.514 – 0.660)	53.23	40.74	76.74	76.73	40.76
MST and SGA	0.574 (0.500 – 0.647)	50.01	33.33	81.40	77.13	39.35
MST and PG-SGA	0.587 (0.514 – 0.660)	53.23	40.74	76.74	76.73	40.76
MST and GLIM	0.586 (0.514 – 0.659)	52.03	37.04	80.23	77.90	40.37
<i>MUST isolated</i>	0.590 (0.516 – 0.665)	59.27	59.88	58.14	72.91	43.50
MUST and SGA	0.593 (0.519 – 0.666)	56.05	48.77	69.77	75.22	41.98
MUST and PG-SGA	0.587 (0.512 – 0.662)	58.87	59.26	58.14	72.71	43.13
MUST and GLIM	0.570 (0.496 – 0.645)	55.65	52.47	61.63	72.01	40.79
<i>PG-SGA SF isolated</i>	0.567 (0.491 – 0.643)	61.28	71.60	41.86	69.86	43.93
PG-SGA SF and SGA	0.606 (0.532 – 0.679)	58.47	53.70	67.44	75.63	43.63
PG-SGA SF and PG-SGA	0.573 (0.497 – 0.649)	61.69	71.60	43.02	70.28	44.60
PG-SGA SF and GLIM	0.563 (0.488 – 0.639)	56.85	58.02	54.65	70.66	40.89

<i>MNA SF isolated</i>	0.571 (0.495 – 0.648)	62.89	75.93	38.37	69.87	45.86
MNA SF and SGA	0.621 (0.548 – 0.694)	60.49	56.79	67.44	76.65	45.34
MNA SF and PG-SGA	0.603 (0.528 – 0.679)	64.91	75.31	45.35	72.17	49.39
MNA SF and GLIM	0.570 (0.495 – 0.645)	58.47	61.73	52.33	70.90	42.08

Readmission (60 days)

<i>NRS-2002 isolated</i>	0.577 (0.457 – 0.696)	62.14	52.00	63.30	13.99	91.99
NRS-2002 and SGA	0.602 (0.481 – 0.722)	66.66	52.00	68.35	15.87	92.54
NRS-2002 and PG-SGA	0.577 (0.457 – 0.696)	62.14	52.00	63.30	13.99	91.99
NRS-2002 and GLIM	0.577 (0.456 – 0.698)	65.43	48.0	67.43	14.47	91.87
<i>MST isolated</i>	0.555 (0.433 – 0.676)	64.61	44.00	66.97	13.27	91.24
MST and SGA	0.592 (0.469 – 0.714)	71.19	44.00	74.31	16.44	92.04
MST and PG-SGA	0.555 (0.433 – 0.676)	64.61	44.00	66.97	13.27	91.24
MST and GLIM	0.576 (0.453 – 0.698)	68.31	44.00	71.10	14.88	91.71
<i>MUST isolated</i>	0.561 (0.444 – 0.678)	49.80	64.00	48.17	12.42	92.10
MUST and SGA	0.603 (0.485 – 0.720)	60.49	60.00	60.55	14.87	92.95
MUST and PG-SGA	0.563 (0.446 – 0.680)	50.21	64.00	48.62	12.51	92.16
MUST and GLIM	0.551 (0.432 – 0.670)	54.32	56.00	54.13	12.29	91.46
<i>PG-SGA SF isolated</i>	0.554 (0.440 – 0.669)	39.10	76.00	34.86	11.81	92.67
PG-SGA SF and SGA	0.602 (0.486 – 0.718)	57.20	64.00	56.42	14.43	93.17
PG-SGA SF and PG-SGA	0.557 (0.442 – 0.671)	39.51	76.00	35.32	11.89	92.76
PG-SGA SF and GLIM	0.541 (0.422 – 0.659)	49.38	60.00	48.17	11.73	91.29

<i>MNA SF isolated</i>	0.621 (0.519 – 0.722)	38.28	92.00	32.11	13.47	97.22
MNA SF and SGA	0.635 (0.525 – 0.746)	56.79	72.00	55.05	15.53	94.48
MNA SF and PG-SGA	0.637 (0.538 – 0.735)	41.16	92.00	35.32	14.04	97.47
MNA SF and GLIM	0.612 (0.502 – 0.722)	49.39	76.00	46.33	13.99	94.39

AUC = Area Under the Curve; ROC = Receiver Operating Characteristic; CI = confidence interval; PPV = Positive predictive value; NPV = Negative predictive value. NRS-2002 = Nutritional Risk Screening; MST = Malnutrition Screening Tool; MUST = Malnutrition Universal Screening Tool; PG-SGA SF = Patient- Generated Subjective Global Assessment Short Form; MNA SF Mini Nutritional Assessment Short Form; SGA = Subjective Global Assessment; PG-SGA = Patient- Generated Subjective Global Assessment;; GLIM = Global Leadership Initiative on Malnutrition.

AUC values = 0.5-0.6 (very bad), 0.6-0.7 (bad), 0.7-0.8 (poor), 0.8-0.9 (good), > 0.9 (excellent) [32]

Sensitivity, specificity, positive predictive value, negative predictive value cutoffs: high: 90% to 100%, moderate: 80% to ≤ 89%; low: ≤ 79% [33]

Prevalence of hospitalization (≥ 4 days) = 65.3%. Prevalence of readmission (60 days) = 10.3%

Table 4. Association of nutritional risk by five screening instruments and malnutrition by three nutritional assessment tools with clinical outcomes in hospitalized elderly cancer patients

Classification of nutritional tools	Hospitalization (≥ 4 days)			60 days readmission		
	OR ^a	95%CI	P value	OR ^a	95%CI	P value
NRS-2002 $\geq 3^b$	2.36	1.20 – 4.61	0.012	1.76	0.67 – 4.58	0.246
NRS-2002 $\geq 3^b$ and SGA (malnourished) ^c	2.23	1.12 – 4.44	0.022	2.15	0.83 – 5.59	0.113
NRS-2002 $\geq 3^b$ and PG-SGA (malnourished) ^d	2.26	1.20 – 4.61	0.012	1.76	0.67 – 4.58	0.246
NRS-2002 $\geq 3^b$ and GLIM (malnourished) ^e	2.28	1.15 – 4.52	0.017	1.79	0.69 – 4.63	0.226
MST $\geq 2^f$	2.10	1.09 – 4.02	0.025	1.73	0.69 – 4.33	0.242
MST $\geq 2^f$ and SGA (malnourished) ^c	1.77	0.88 – 3.57	0.108	2.13	0.84 – 5.38	0.109
MST $\geq 2^f$ and PG-SGA (malnourished) ^d	2.10	1.09 – 4.02	0.025	1.73	0.69 – 4.33	0.242
MST $\geq 2^f$ and GLIM (malnourished) ^e	2.11	1.06 – 4.20	0.032	1.95	0.77 – 4.90	0.156
MUST $\geq 1^g$	2.02	1.12 – 3.64	0.018	1.73	0.69 – 4.73	0.241
MUST $\geq 1^g$ and SGA (malnourished) ^c	1.79	0.97 – 3.32	0.062	2.25	0.88 – 5.77	0.090
MUST $\geq 1^g$ and PG-SGA (malnourished) ^d	1.96	1.09 – 3.53	0.023	1.75	0.69 – 4.41	0.232
MUST $\geq 1^g$ and GLIM (malnourished) ^e	1.70	0.94 – 3.06	0.077	1.60	0.65 – 3.94	0.303

PG-SGA SF $\geq 4^h$	1.47	0.78 – 2.77	0.226	1.47	0.50 – 4.27	0.479
PG-SGA SF $\geq 4^h$ and SGA (malnourished) ^c	1.83	0.98 – 3.44	0.057	2.10	0.76 – 5.77	0.151
PG-SGA SF $\geq 4^h$ and PG-SGA (malnourished) ^d	1.51	0.80 – 2.83	0.198	1.55	0.53 – 4.54	0.417
PG-SGA SF $\geq 4^h$ and GLIM (malnourished) ^e	1.41	0.77 – 2.58	0.260	1.22	0.47 – 3.14	0.675
MNA SF $\leq 11^i$	1.85	0.98 – 3.46	0.054	5.14	1.13 – 23.37	0.034
MNA SF $\leq 11^i$ and SGA (malnourished) ^c	2.19	1.18 – 4.04	0.012	3.14	1.10 – 8.91	0.031
MNA SF $\leq 11^i$ and PG-SGA (malnourished) ^d	2.48	1.32 – 4.64	0.004	6.04	1.31 – 27.73	0.021
MNA SF $\leq 11^i$ and GLIM (malnourished) ^e	1.60	0.88 – 2.91	0.117	2.57	0.93 – 7.13	0.068

OR = Odds Ratio; CI = confidence interval; NRS-2002 = Nutritional Risk Screening; MST = Malnutrition Screening Tool; MUST = Malnutrition Universal Screening Tool; PG-SGA SF = Patient- Generated Subjective Global Assessment Short Form; MNA SF Mini Nutritional Assessment Short Form; SGA = Subjective Global Assessment; PG-SGA = Patient- Generated Subjective Global Assessment; GLIM = Global Leadership Initiative on Malnutrition;

^a Obtained by multiple logistic regression analysis. Models adjusted for age, sex, type of cancer, presence of metastasis, and chronic diseases.

^b Reference category: Patients with NRS-2002 score ≥ 3 ;

^{c, d, e} Reference category: Patients well-nourished.

^f Reference category: Patients with MST score ≥ 2 ;

^g Reference category: Patients with MUST score ≥ 1 ;

^h Reference category: Patients with PG-SGA SF score ≥ 4 ;

ⁱ Reference category: Patients with MNA SF \leq score 11

ANEXOS



EDITORIAL CERTIFICATE

This document certifies that the manuscript below was edited for correct English language usage, grammar, punctuation and spelling by qualified editors at Scientific Linguagem.

Paper Title:

Complementarity of nutritional assessment tools to predict prolonged hospital stay and readmission in older patients with cancer

Authors:

Giovanna Potrick Stefani
Mariana Scortegagna Crestani
Laura Machado Scott
Camilla Horn Soares
Thais Steemburgo

Date certificate issued:

January 2023

For further information please contact Ms. Graça Adam at +55-51-3012.0575 or artigos@scientific.com.br.



NUTRITION

The International Journal of Applied and Basic Nutritional Sciences

AUTHOR INFORMATION PACK

TABLE OF CONTENTS

• Description	p.1
• Impact Factor	p.1
• Abstracting and Indexing	p.1
• Editorial Board	p.2
• Guide for Authors	p.4



ISSN: 0899-9007

DESCRIPTION

Founded by Michael M. Meguid in the early 1980's, Nutrition presents advances in nutrition research and science, informs its readers on new and advancing technologies and data in **clinical nutrition** practice, encourages the application of outcomes research and meta-analyses to problems in patient-related nutrition; and seeks to help clarify and set the research, policy and practice agenda for **nutrition science** to enhance human well-being in the years ahead. **Papers on nutrition-related plant or animal sciences are unlikely to be considered as they are outside the main focus of the Journal.**

Benefits to authors

We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our [author services](#).

Please see our [Guide for Authors](#) for information on article submission. If you require any further information or help, please visit our [Support Center](#)

IMPACT FACTOR

2021: 4.893 © Clarivate Analytics Journal Citation Reports 2022

ABSTRACTING AND INDEXING

PubMed/Medline
Current Contents - Life Sciences
Automatic Subject Citation Alert
CAB International
Web of Science
CINAHL
Embase
Referativnyi Zhurnal VINTI-RAN (Russian Academy of Sciences)
Science Citation Index
PubMed/Medline
FSTA (Food Science and Technology Abstracts)
Scopus

EDITORIAL BOARD

Editor in Chief

Alessandro Laviano, Roma, Italy

Deputy Editor in Chief

M. Isabel T.D. Correia, BELO HORIZONTE, Minas Gerais, Brazil

Managing Editor

Dawn L. Jensen-Nobile, Wenatchee, Washington, United States of America

Associate Editors

Internal Medicine & ICU

William Manzanares, Montevideo, Uruguay

Micronutrients

Jan Frank, Stuttgart, Germany

Pediatrics

Giovanni Di Nardo, Roma, Italy

Cancer

Marilia Seelaender, Sao Paulo, Brazil

Epidemiology

Anette Buyken, Paderborn, Germany

Nutritional Status Assessment

Janicke Visser, Stellenbosch, South Africa

Surgery

Arved Weimann, Leipzig, Germany

Editors Emeritus

Hans Biesalski

Antonio Campos

Marietjie Herselman

Tsann-Long Hwang

Demetre Labadarios

Peter James Little

Ibolya Nyulasi

Harumasa Ohyanagi

Alan Shenkin

Editorial Advisory Board Members

Mahinda Abeywardena, Adelaide, Australia

Kasim Abdulkerim Baltaci, Konya, Turkey

Larry Bernstein, Trumbull, Connecticut, United States of America

Federico Bozzetti, Prato, Italy

Riccardo Caccialanza, Pavia, Italy

Tommy Cederholm, Uppsala, Sweden

Chih-Yen Chen, Taipei, Taiwan

Evan Paul Cherniack, Miami, Florida, United States of America

Salvatore Chirumbolo, Verona, Italy

Agata Chmurzynska, Poznan, Poland

Yunhi Cho, Yongin, South Korea

Martin Crook, London, United Kingdom

Undurti Narasimha Das, Shaker Heights, Ohio, United States of America

Mark Daniel DeBoer, Charlottesville, Virginia, United States of America

Yalim Dikmen, Istanbul, Turkey

Hassan I. H. El-Sayyad, El Mansoura, Egypt

Frida Fåk, Lund, Sweden

Serguei Fetissov, Rouen, France

Ioannis Gioulbasanis, Larissa, Greece

Michael J. Glade, Kailua Kona, United States of America

Sitang Gong, Guangzhou, China

Martin Gotteland, Santiago, Chile

Tilman Grune, Nuthetal, Germany
Per-Olof Hasselgren, Boston, Massachusetts, United States of America
Venkatesh L. Hegde, Columbia, South Carolina, United States of America
Sandra Hirsch, Macul, Chile
Motoyuki Iemitsu, Kusatsu, Japan
Akio Inui, Kagoshima, Japan
Keiji Iriyama, Tsu, Japan
Kursheed Jeejeebhoy, Toronto, Ontario, Canada
Zhu-Ming Jiang, Dong Cheng Qu, China
Haruki Koike, Nagoya, Japan
Regina Komsa-Penkova, Pleven, Bulgaria
Irina Korichneva, Amiens, France
Zeljko Krznaric, Zagreb, Croatia
Jacqueline Alvarez Leite, BELO HORIZONTE, Minas Gerais, Brazil
Peter James Little, Melbourne, Victoria, Australia
Henry Lukaski, Grand Forks, North Dakota, United States of America
Alessio Molfino, Roma, Italy
Timothy Moran, Baltimore, Maryland, United States of America
Sergiy Nadtochiy, Rochester, New York, United States of America
Yutaka Nakaya, Tokushima, Japan
Etsuo Niki, Chiyoda-Ku, Japan
Donatus Nohr, Ostfildern, Germany
Allal Ouhtit, Muscat, Oman
Vladimir Palicka, Hradec Králové, Czechia
Marek Pertkiewicz, Warszawa, Poland
Claude Pichard, Geneva, Switzerland
Loris Pironi, Bologna, Italy
Lindsay Plank, Auckland, New Zealand
Ryszard Pluta, Warszawa Poland
Sunil Rangarajan, Birmingham, Alabama, United States of America
Lidia Santarpia, Napoli, Italy
Stephane Schneider, Nice, France
Han Ping Shi, Beijing, China
Pierre Singer, Tel Aviv, Israel
Lubos Sobotka, Hradec Králové, Czechia
Noel Solomons, Guatemala City, Guatemala
Krishnan Sriram, Downers Grove Illinois, United States of America
Analia Lorena Tomat, Buenos Aires, Argentina
Luzia Valentini, Neubrandenburg, Germany
Nguyen Van Nhien, Hanoi, Viet Nam
Xiaodong Zhou, Loma Linda, California, United States of America
Thomas R. Ziegler, Atlanta, Georgia, United States of America

GUIDE FOR AUTHORS

Please note that per 1 January 2019 the Nutrition Guide for Authors has been updated in regards to the requirements for the submission of clinical trials. See further details below.

INTRODUCTION

Nutrition provides an international forum for professionals interested in the **applied and basic biomedical nutritional sciences, and publishes papers both of clinical interest and of scientific import**. Investigators are encouraged to submit papers in the disciplines of nutritionally related biochemistry, genetics, immunology, metabolism, molecular and cell biology, neurobiology, physiology, and pharmacology. Papers on nutrition-related plant or animal sciences which are not of direct relevance to man, whereas occasionally of interest are not the main focus of the Journal.

Nutrition publishes a wide range of articles, which includes original investigations, review articles, rapid communications, research letters, case reports and special category manuscripts. Manuscripts must be prepared in accordance with the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" developed by the International Committee of Medical Journal Editors (*N Engl J Med* 1991;324:424-428). All submissions are peer reviewed.

Original Investigation (3000-5000 words including tables, figures and references)

Original investigations are considered full-length applied (human) or basic (bench work) research reports. They cover topics relevant to clinical and basic studies relevant to man in the following areas nutritionally related biochemistry, genetics, immunology, metabolism, molecular and cell biology, neurobiology, physiology, and pharmacology. Studies in adult and pediatric populations are welcome. The work presented in the manuscript must be original; studies confirming previous observations will be considered. Other considerations of a paper's publishability are its importance to the science, the soundness of the experimental design, the validity of methods, the appropriateness of the conclusions and the quality of presentation.

Rapid Communication (1000-3000 words including tables, figures and references)

Papers representing concise and original studies of scientific importance are considered. In the cover letter the author should justify the request for Rapid Communication. The review process is 10 days, authors are allowed one revision if accepted, and the final version of the paper appears in the next available issue of the journal.

Research Letter (up to 1000 words, including up to 10 references and 1 figure or table)

A Research Letter contains new data or a clinical observation, in a format that allows for rapid publication.

Review Article (up to 5000 words including tables, figures and references)

In-depth, comprehensive state of the art reviews on a nutritional topic are welcomed. Reviews may be invited by the Editor or may be unsolicited viewpoints.

Case Report (up to 2500 words including tables figures, and references) Case Reports include case studies of 4 or fewer patients that describe a novel situation or add important insights into mechanisms, diagnosis or treatment of a disease.

Editorial (up to 1000 words including tables, figures and references)

Editorials express opinions on current topics of interest, or provide comments on papers published in *Nutrition* or other journals. Editorials are generally solicited by one of the Editors.

Correspondence (Letter to the Editor) (1000 words including tables, figures and references)

Opinion pieces concerning papers published in *Nutrition* are particularly welcomed and all submissions are subject to editing. Letters commenting on past-published papers are sent to the corresponding author for a response. Letters are selected for their relevance and originality; not all letters submitted can be published.

Meeting Proceedings (up to 2500 words including tables, figures and references)

Reports of meeting proceedings are synopses of scientific meetings of interest to *Nutrition's* audience. Authors should e-mail the Editor to solicit potential interest 8 weeks prior to conference.

Collections of abstracts representing the proceedings of organizational meetings are not subjected to customary peer review. It is the view of the Editorial Board that it is of service to the nutrition community to present such material as promptly as possible.

Hypothesis (up to 3000 words including tables, figures and references)

Novel insights into a significant questions or clinical issues are welcome, and will be peer reviewed. As the definition of 'hypothesis' suggests, articles of this type should be, although they lack direct experimental evidence, closely tied to empirical data and lead to testable predictions.

Special Article (up to 5000 words including tables, figures and references)

Associated with a particular special event, invitation or announcement; for example, the annual John M. Kinney Awards papers.

Submission checklist

Ensure that the following information and files have been included. One author has been designated as the corresponding author with contact details: E-mail address Full postal address

Manuscript: Word doc or similar required. PDF is not suitable for review and production. Include keywords. Has been spell-checked and grammar checked. Has been edited by professional, preferably native-English-speaking editor.

Tables: Include titles, description, footnotes. Create tables in the document rather than inserting image files, so that changes can be made.

Figures: High quality and good resolution. Provide separate image files as well as in-manuscript. Include relevant captions. Indicate clearly if color should be used for any figures in print. Ensure all figure and table citations in the text match the files provided.

If applicable include as separate files: Graphical abstracts Highlights (3-5, document file) Supplemental files

References: All references mentioned in the Reference List are cited in the text, and vice versa. Make sure reference style is consistent throughout.

Further considerations: Permission has been obtained for use of copyrighted material from other sources (including the Internet). Relevant declarations of interest have been made. Journal policies detailed in this guide have been reviewed. Referee suggestions and contact details provided, based on journal requirements.

Your Paper Your Way

We now differentiate between the requirements for new and revised submissions. You may choose to submit your manuscript as a single Word or PDF file to be used in the refereeing process. Only when your paper is at the revision stage, will you be requested to put your paper in to a 'correct format' for acceptance and provide the items required for the publication of your article.

To find out more, please visit the Preparation section below.

BEFORE YOU BEGIN

Ethics in publishing

Please see our information on [Ethics in publishing](#).

CONDITIONS OF PUBLICATION – ETHICAL AND LEGAL CONSIDERATIONS

All material submitted to *Nutrition*, for any section of the journal, is considered for publication on the understanding that authors (including all coauthors) agree to *Nutrition's* publication policies as stated in this section of the Guidelines to Authors.

In the event of non-compliance with these conditions of publication, including issues that surface after a contribution is published, *Nutrition's* rights include: sending a notice of failure to comply to authors' employers and funding agencies; and/or informing readers via a published correction/retraction; the latter is linked to the original contribution via electronic indexing and becomes part of the formal published record.

Research/publication misconduct is a serious breach of ethics. Such misconduct includes:

- i) Redundant or duplicate publication by same author(s),
- ii) Publication in another source by the same author(s) without acknowledgement or permission from the publisher, or
- iii) Plagiarism or self-plagiarism (publication of material without acknowledging original author source).
- iv) Fabrication of data, not substantiable via review of research records.

Should such publications occur, editorial action would be taken. In certain cases, secondary publication is justifiable and even beneficial; however, such circumstances should be prospectively discussed with and agreed upon by the Editor-In-Chief.

Nutrition will not accept a submission of work previously reported in large part in a published article (duplicate) or that is contained in another paper submitted or accepted for publication in *Nutrition* or elsewhere.

Informed consent and patient details

Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in the paper. Appropriate consents, permissions and releases must be obtained where an author wishes to include case details or other personal information or images of patients and any other individuals in an Elsevier publication. Written consents must be retained by the author but copies should not be provided to the journal. Only if specifically requested by the journal in exceptional circumstances (for example if a legal issue arises) the author must provide copies of the consents or evidence that such consents have been obtained. For more information, please review the [Elsevier Policy on the Use of Images or Personal Information of Patients or other Individuals](#). Unless you have written permission from the patient (or, where applicable, the next of kin), the personal details of any patient included in any part of the article and in any supplementary materials (including all illustrations and videos) must be removed before submission.

Declaration of competing interest

Corresponding authors, on behalf of all the authors of a submission, must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. All authors, including those *without* competing interests to declare, should provide the relevant information to the corresponding author (which, where relevant, may specify they have nothing to declare). Corresponding authors should then use [this tool](#) to create a shared statement and upload to the submission system at the Attach Files step. **Please do not convert the .docx template to another file type. Author signatures are not required.**

Submission declaration and verification

Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see '[Multiple, redundant or concurrent publication](#)' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify compliance, your article may be checked by [Crossref Similarity Check](#) and other originality or duplicate checking software.

Preprints

Please note that [preprints](#) can be shared anywhere at any time, in line with Elsevier's [sharing policy](#). Sharing your preprints e.g. on a preprint server will not count as prior publication (see '[Multiple, redundant or concurrent publication](#)' for more information).

Use of inclusive language

Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias,

stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. When coding terminology is used, we recommend to avoid offensive or exclusionary terms such as "master", "slave", "blacklist" and "whitelist". We suggest using alternatives that are more appropriate and (self-) explanatory such as "primary", "secondary", "blocklist" and "allowlist". These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive.

Reporting sex- and gender-based analyses

Reporting guidance

For research involving or pertaining to humans, animals or eukaryotic cells, investigators should integrate sex and gender-based analyses (SGBA) into their research design according to funder/ sponsor requirements and best practices within a field. Authors should address the sex and/or gender dimensions of their research in their article. In cases where they cannot, they should discuss this as a limitation to their research's generalizability. Importantly, authors should explicitly state what definitions of sex and/or gender they are applying to enhance the precision, rigor and reproducibility of their research and to avoid ambiguity or conflation of terms and the constructs to which they refer (see Definitions section below). Authors can refer to the [Sex and Gender Equity in Research \(SAGER\) guidelines](#) and the [SAGER guidelines checklist](#). These offer systematic approaches to the use and editorial review of sex and gender information in study design, data analysis, outcome reporting and research interpretation - however, please note there is no single, universally agreed-upon set of guidelines for defining sex and gender.

Definitions

Sex generally refers to a set of biological attributes that are associated with physical and physiological features (e.g., chromosomal genotype, hormonal levels, internal and external anatomy). A binary sex categorization (male/female) is usually designated at birth ("sex assigned at birth"), most often based solely on the visible external anatomy of a newborn. Gender generally refers to socially constructed roles, behaviors, and identities of women, men and gender-diverse people that occur in a historical and cultural context and may vary across societies and over time. Gender influences how people view themselves and each other, how they behave and interact and how power is distributed in society. Sex and gender are often incorrectly portrayed as binary (female/male or woman/man) and unchanging whereas these constructs actually exist along a spectrum and include additional sex categorizations and gender identities such as people who are intersex/have differences of sex development (DSD) or identify as non-binary. Moreover, the terms "sex" and "gender" can be ambiguous—thus it is important for authors to define the manner in which they are used. In addition to this definition guidance and the SAGER guidelines, the [resources on this page](#) offer further insight around sex and gender in research studies.

Author contributions

For transparency, we encourage authors to submit an author statement file outlining their individual contributions to the paper using the relevant CRediT roles: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Roles/Writing - original draft; Writing - review & editing. Authorship statements should be formatted with the names of authors first and CRediT role(s) following. [More details and an example](#).

Authorship

Corresponding Author: One author is designated the corresponding author (not necessarily the senior author) who will be approached to clarify any issues, such as those pertaining to materials and methods, or technical comments. If *Nutrition* receives feedback from its readers concerning the published paper, the corresponding author will be contacted. It is this author's responsibility to inform all coauthors of such matters to ensure they are dealt with promptly.

The corresponding author must affirm in the cover letter at the time of submission that:

1. None of the material in the manuscript is included in another manuscript, has been published previously, or is currently under consideration for publication elsewhere. This includes symposia proceedings, transactions, books, articles published by invitation, and preliminary publications of any kind except an abstract of less than 250 words. If there is any question concerning potential overlap, the related material must be included for evaluation.

2. Ethical guidelines were followed by the investigator in performing studies on humans or animals and should be described in the paper. The approval of the institutional review board of either animal or human ethics committee must be cited in the Methods.

3. Each author must have participated sufficiently in the work to take public responsibility for the content of the paper and must approve of the final version of the manuscript. Authorship should be based on substantive contributions to each of the following: conception and design of the study; generation, collection, assembly, analysis and/or interpretation of data; and drafting or revision of the manuscript; approval of the final version of the manuscript. Authors are required to include a statement in the Acknowledgements to specify the actual contribution of each coauthor under the above headings.

4. If requested, the authors will provide the data or will cooperate fully in obtaining and providing the data on which the manuscript is based for examination by the editors or their assignees

Changes to Authorship

This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts:

Changes to author names after acceptance are strongly discouraged and can be accepted only in compelling circumstances.

Before the accepted manuscript is published in an online issue Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager from the corresponding author of the accepted manuscript and must include: (a) the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Requests that are not sent by the corresponding author will be forwarded by the Journal Manager to the corresponding author, who must follow the procedure as described above. Note that: (1) Journal Managers will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until authorship has been agreed.

After the accepted manuscript is published in an online issue: Any requests to add, delete, or rearrange author names in an article published in an online issue will follow the same policies as noted above and result in a corrigendum.

Reporting clinical trials

Randomized controlled trials should be presented according to the CONSORT guidelines. At manuscript submission, authors must provide the CONSORT checklist accompanied by a flow diagram that illustrates the progress of patients through the trial, including recruitment, enrollment, randomization, withdrawal and completion, and a detailed description of the randomization procedure. The [CONSORT checklist and template flow diagram](#) are available online.

Registration of Clinical Trials

Registration in a public trials registry is a condition for publication of clinical trials in this journal in accordance with [International Committee of Medical Journal Editors](#) recommendations. Trials must register at or before the onset of patient enrollment. The clinical trial registration number should be included at the end of the abstract of the article. A clinical trial is defined as any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects of health outcomes. Health-related interventions include any intervention used to modify a biomedical or health-related outcome (for example drugs, surgical procedures, devices, behavioural treatments, dietary interventions, and process-of-care changes). Health outcomes include any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. Purely observational studies (those in which the assignment of the medical intervention is not at the discretion of the investigator) will not require registration.

Article transfer service

This journal uses the Elsevier Article Transfer Service to find the best home for your manuscript. This means that if an editor feels your manuscript is more suitable for an alternative journal, you might be asked to consider transferring the manuscript to such a journal. The recommendation might be provided by a Journal Editor, a dedicated [Scientific Managing Editor](#), a tool assisted recommendation, or a combination. If you agree, your manuscript will be transferred, though you will have the opportunity to make changes to the manuscript before the submission is complete. Please note that your manuscript will be independently reviewed by the new journal. [More information](#).

Copyright

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see [more information](#) on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. [Permission](#) of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has [preprinted forms](#) for use by authors in these cases.

For gold open access articles: Upon acceptance of an article, authors will be asked to complete a 'License Agreement' ([more information](#)). Permitted third party reuse of gold open access articles is determined by the author's choice of [user license](#).

Author rights

As an author you (or your employer or institution) have certain rights to reuse your work. [More information](#).

Elsevier supports responsible sharing

Find out how you can [share your research](#) published in Elsevier journals.

Role of the funding source

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement, it is recommended to state this.

Open Access

Please visit our [Open Access page](#) for more information.

Elsevier Researcher Academy

[Researcher Academy](#) is a free e-learning platform designed to support early and mid-career researchers throughout their research journey. The "Learn" environment at Researcher Academy offers several interactive modules, webinars, downloadable guides and resources to guide you through the process of writing for research and going through peer review. Feel free to use these free resources to improve your submission and navigate the publication process with ease.

Language (usage and editing services)

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the [English Language Editing service](#) available from Elsevier's Author Services.

Submission

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

Submit your article

All new manuscripts must be submitted through Nutrition's online submission and review Web site <https://www.editorialmanager.com/nut>

Suggesting reviewers

Please submit the names and institutional e-mail addresses of several potential reviewers.

You should not suggest reviewers who are colleagues, or who have co-authored or collaborated with you during the last three years. Editors do not invite reviewers who have potential competing interests with the authors. Further, in order to provide a broad and balanced assessment of the work, and ensure scientific rigor, please suggest diverse candidate reviewers who are located in different countries/regions from the author group. Also consider other diversity attributes e.g. gender, race and ethnicity, career stage, etc. Finally, you should not include existing members of the journal's editorial team, of whom the journal are already aware.

Note: the editor decides whether or not to invite your suggested reviewers.

PREPARATION

NEW SUBMISSIONS

Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts your files to a single PDF file, which is used in the peer-review process.

As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file to be used in the refereeing process. This can be a PDF file or a Word document, in any format or layout that can be used by referees to evaluate your manuscript. It should contain high enough quality figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at the initial submission. Please note that individual figure files larger than 10 MB must be uploaded separately.

Formatting author group

Omission of titles after author names is required, since they can create confusion and misunderstandings, and delay publication time.

References

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the article number or pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct.

Formatting requirements

There are no strict formatting requirements but all manuscripts must contain the essential elements needed to convey your manuscript, for example Abstract, Keywords, Introduction, Materials and Methods, Results, Conclusions, Artwork and Tables with Captions.

If your article includes any Videos and/or other Supplementary material, this should be included in your initial submission for peer review purposes.

Divide the article into clearly defined sections.

Figures and tables embedded in text

Please ensure the figures and the tables included in the single file are placed next to the relevant text in the manuscript, rather than at the bottom or the top of the file. The corresponding caption should be placed directly below the figure or table.

The peer review process

Double anonymized review

This journal operates a double anonymized review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. Editors are not involved in decisions about papers which they have written themselves or have been written by family members or colleagues or which relate to products or services in which the

editor has an interest. Any such submission is subject to all of the journal's usual procedures, with peer review handled independently of the relevant editor and their research groups. [More information on types of peer review](#).

Anonymized review means the identities of the authors are concealed from the reviewers, and vice versa. [More information](#) is available on our website. To facilitate this, please include the following separately:

Title page (with author details): This should include the title, authors' names, affiliations, acknowledgements and any Declaration of Interest statement, and a complete address for the corresponding author including an e-mail address.

Anonymized manuscript (no author details): The main body of the paper (including the references, figures, tables and any acknowledgements) should not include any identifying information, such as the authors' names or affiliations.

An outline of what to expect, for this journal, from receipt of submission to first decision

The Managing Editor determines, generally within a week, whether the language and presentation are sufficiently clear for the review process, and whether there are any ethical or basic quality issues. If there are any concerns, the manuscript may be returned to the author for a chance to improve the manuscript. If the manuscript is then deemed clear and ethical, it goes to the Editor in Chief or Deputy Editor in Chief. Authors sometimes ask why the English must be improved at this stage, as it takes time and can be costly. The reason is that it helps us to engage the services of expert reviewers within a reasonable time frame, as they receive many requests, and helps all who check the manuscript to be sure of the authors' meaning from the start. Elsevier has an English-editing service, but authors are free to use any editor they like, as long as the result is a manuscript in which the science and methods are explained clearly. The Editor in Chief determines, also generally within a week, whether the science and methods are sufficiently sound for peer review, and the topic important enough for consideration of publication in this particular journal. If the manuscript passes this stage, it goes on to the Associate Editor. The Associate Editor manages the review process. Only a few reviewers can be invited at a time, and they are each allowed a maximum of five workdays to respond. If they agree to our request, they are given 14 days to review the manuscript. If they are late, they are sent reminders. If they do not respond to reminders, they are uninvited and a new reviewer is invited in their place. When the Associate Editor determines that a sufficient amount of input has been provided by the reviewers, a decision is made. The decision may require further confirmation from the Editor in Chief. If, after 90 days from the date of submission, outside reviewer input is still deemed insufficient, the Associate Editor is required to make, in consultation with other editors or board members if needed, their own decision.

REVISED SUBMISSIONS

Use of word processing software

Regardless of the file format of the original submission, at revision you must provide us with an editable file of the entire article. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the [Guide to Publishing with Elsevier](#)). See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

Article structure

Subdivision - unnumbered sections

Divide your article into clearly defined sections. Each subsection is given a brief heading. Each heading should appear on its own separate line. Subsections should be used as much as possible when cross-referencing text: refer to the subsection by heading as opposed to simply 'the text'.

Introduction

State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

Material and methods

Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference. If quoting directly from a previously published method, use quotation marks and also cite the source. Any modifications to existing methods should also be described.

Theory/calculation

A Theory section should extend, not repeat, the background to the article already dealt with in the Introduction and lay the foundation for further work. In contrast, a Calculation section represents a practical development from a theoretical basis.

Results

Results should be clear and concise.

Discussion

This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

Conclusions

The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

Appendices

If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.

This should include 1) title of paper (**use no abbreviations, limit: 120 characters with spaces**), 2) running head of fewer than 55 characters with spaces, 3) full names of all authors with highest academic degree(s); 4) affiliations of all authors; 4) role of each author in the work (see Authorship); 5) a word count for the entire manuscript (including figures and tables), and the number of figures and tables, 4) the complete mailing address (including telephone, fax, and e-mail address of the corresponding author for e-mailing of proofs and reprint requests).

Highlights

Highlights are mandatory for this journal as they help increase the discoverability of your article via search engines. They consist of a short collection of bullet points that capture the novel results of your research as well as new methods that were used during the study (if any). Please have a look at the examples here: [example Highlights](#).

Highlights should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point).

Abstracts should be no more than **250 words**. The structured abstract for an original investigation should be organized as follows:

Objective: The abstract should begin with a clear statement of the precise objective or question addressed in the paper. If a hypothesis was tested, it should be stated.

Research Methods & Procedures: The basic design of the study and its duration should be described. The methods used should be stated, the statistical data/methods provided and referenced.

Results: The main results of the study should be given in narrative form. Measurements or other information that may require explanation should be defined. Levels of statistical significance should be indicated, including other factors crucial to the outcome of the study.

Conclusion(s): State only conclusions that are directly supported by the evidence and the implications of the findings.

Graphical abstract

Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a

separate file in the online submission system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view [Example Graphical Abstracts](#) on our information site.

Keywords

5–7 key words or phrases should be provided which should be selected from the body of the text and not duplicate title words.

Abbreviations

Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

Acknowledgments

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

Formatting of funding sources

List funding sources in this standard way to facilitate compliance to funder's requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, it is recommended to include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Units

Follow internationally accepted rules and conventions: use the international system of units (SI). If other units are mentioned, please give their equivalent in SI.

Math formulae

Please submit math equations as editable text and not as images. Present simple formulae in line with normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

Footnotes

Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors build footnotes into the text, and this feature may be used. Should this not be the case, indicate the position of footnotes in the text and present the footnotes themselves separately at the end of the article.

Artwork

Electronic artwork

General points

- Make sure you use uniform lettering and sizing of your original artwork.
- Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Indicate per figure if it is a single, 1.5 or 2-column fitting image.
- For Word submissions only, you may still provide figures and their captions, and tables within a single file at the revision stage.
- Please note that individual figure files larger than 10 MB must be provided in separate source files.

A detailed [guide on electronic artwork](#) is available.

You are urged to visit this site; some excerpts from the detailed information are given here.

Formats

Regardless of the application used, when your electronic artwork is finalized, please 'save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'.

TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi.

TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi.

TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi is required.

Please do not:

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low.
- Supply files that are too low in resolution.
- Submit graphics that are disproportionately large for the content.

Color artwork

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. **For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article.** Please indicate your preference for color: in print or online only. [Further information on the preparation of electronic artwork.](#)

Figure captions

Ensure that each illustration has a caption. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

Tables

Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

References

Citation in text

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

Reference links

Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, Crossref and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is highly encouraged.

A DOI is guaranteed never to change, so you can use it as a permanent link to any electronic article. An example of a citation using DOI for an article not yet in an issue is: VanDecar J.C., Russo R.M., James D.E., Ambeh W.B., Franke M. (2003). Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. *Journal of Geophysical Research*, <https://doi.org/10.1029/2001JB000884>. Please note the format of such citations should be in the same style as all other references in the paper.

Web references

As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

Data references

This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

Preprint references

Where a preprint has subsequently become available as a peer-reviewed publication, the formal publication should be used as the reference. If there are preprints that are central to your work or that cover crucial developments in the topic, but are not yet formally published, these may be referenced. Preprints should be clearly marked as such, for example by including the word preprint, or the name of the preprint server, as part of the reference. The preprint DOI should also be provided.

References in a special issue

Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

Reference management software

Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support [Citation Style Language styles](#), such as [Mendeley](#). Using citation plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide. If you use reference management software, please ensure that you remove all field codes before submitting the electronic manuscript. [More information on how to remove field codes from different reference management software.](#)

Reference formatting

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the article number or pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:

Reference style

Text: Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always be given.

List: Number the references (numbers in square brackets) in the list in the order in which they appear in the text.

Examples:

Reference to a journal publication:

[1] Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. *J Sci Commun* 2010;163:51–9. <https://doi.org/10.1016/j.Sc.2010.00372>.

Reference to a journal publication with an article number:

[2] Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. *Heliyon*. 2018;19:e00205. <https://doi.org/10.1016/j.heliyon.2018.e00205>

Reference to a book:

[3] Strunk Jr W, White EB. *The elements of style*. 4th ed. New York: Longman; 2000.

Reference to a chapter in an edited book:

[4] Mettam GR, Adams LB. How to prepare an electronic version of your article. In: Jones BS, Smith RZ, editors. *Introduction to the electronic age*, New York: E-Publishing Inc; 2009, p. 281–304.

Reference to a website:

[5] Cancer Research UK. Cancer statistics reports for the UK, <http://www.cancerresearchuk.org/aboutcancer/statistics/cancerstatsreport/>; 2003 [accessed 13 March 2003].

Reference to a dataset:

[dataset] [6] Oguro M, Imahiro S, Saito S, Nakashizuka T. Mortality data for Japanese oak wilt disease and surrounding forest compositions, Mendeley Data, v1; 2015. <https://doi.org/10.17632/xwj98nb39r.1>.

Note shortened form for last page number. e.g., 51–9, and that for more than 6 authors the first 6 should be listed followed by 'et al.' For further details you are referred to 'Uniform Requirements for Manuscripts submitted to Biomedical Journals' (J Am Med Assoc 1997;277:927–34) (see also [Samples of Formatted References](#)).

Journal abbreviations source

Journal names should be abbreviated according to the [List of Title Word Abbreviations](#).

Video

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the file in one of our recommended file formats with a preferred maximum size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including [ScienceDirect](#). Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our [video instruction pages](#). Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

Data visualization

Include interactive data visualizations in your publication and let your readers interact and engage more closely with your research. Follow the instructions [here](#) to find out about available data visualization options and how to include them with your article.

Supplementary material

Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

Research data

This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the [research data](#) page.

Data linking

If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the [database linking page](#).

For [supported data repositories](#) a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

Data statement

To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the [Data Statement page](#).

AFTER ACCEPTANCE

Online proof correction

To ensure a fast publication process of the article, we kindly ask authors to provide us with their proof corrections within two days. Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

Offprints

The corresponding author will, at no cost, receive a customized [Share Link](#) providing 50 days free access to the final published version of the article on [ScienceDirect](#). The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Corresponding authors who have published their article gold open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

AUTHOR INQUIRIES

Visit the [Elsevier Support Center](#) to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.

You can also [check the status of your submitted article](#) or find out [when your accepted article will be published](#).

© Copyright 2018 Elsevier | <https://www.elsevier.com>